Expandable support frame and medical device

Information

  • Patent Grant
  • 11406495
  • Patent Number
    11,406,495
  • Date Filed
    Monday, November 6, 2017
    7 years ago
  • Date Issued
    Tuesday, August 9, 2022
    2 years ago
Abstract
Support frames and medical devices are described. An example medical device comprises an expandable support frame with first and second leaflets attached to the support frame. Each of the first and second leaflets defines a domed radius that is equal to or less than the radius of the expandable support frame when the expandable support frame is in an expanded configuration and the leaflets are subjected to fluid pressure sufficient to affect closure of the valve orifice.
Description
FIELD

The disclosure relates generally to the field of implantable medical devices. More particularly, the disclosure relates to intraluminal support frames and medical devices. Particular embodiments relating to intraluminal valve devices and support frames suitable for use in such devices are described in detail.


BACKGROUND

Expandable intraluminal support frames have proven useful in the medical arts. Some expandable support frames are useful without inclusion of any additional elements. Stents, for example, are routinely used in several body lumens as a means for providing support to ailing vessels, such as coronary and non-coronary vessels. In some medical devices, an expandable support frame provides a scaffold onto which one or more additional elements can be attached to achieve a desired function. Occlusion devices, for example, often include a graft or other sheet-like material attached to an expandable support frame.


Constructed in this way, these medical devices can be delivered and deployed intraluminally to substantially block fluid flow through a body vessel. Similarly, some valve devices include a leaflet or leaflets attached to an expandable support frame in a manner that allows the leaflet or leaflets to move between open and closed positions. Constructed in this way, these medical devices can be delivered and deployed intraluminally to regulate fluid flow through a body vessel.


Considering these roles of intraluminal support frames in the medical arts, a need exists for improved frames. Furthermore, for the various types of intraluminal medical devices that include a support frame and one or more additional elements, a need exists for improved frames that improve the effectiveness of the composite device.


Valve devices provide an example. Several researchers have pursued the development of prosthetic valves that are implantable by minimally invasive techniques. Indeed, the art now contains several examples of implantable venous valve devices. Many of these prior art devices include an expandable support frame and an attached graft member that is fashioned into a valve that regulates fluid flow through the device and, ultimately, a body vessel. For example, a graft member can be in the form of a leaflet that is attached to a support frame and movable between first and second positions. In a first position, the valve is open and allows fluid flow to proceed through a vessel in a first direction, and in a second position the valve is closed to prevent fluid flow in a second, opposite direction. Examples of this type of prosthetic valve are described in commonly owned U.S. Pat. No. 6,508,833 to Pavcnik for a MULTIPLE-SIDED INTRALUMINAL MEDICAL DEVICE, which is hereby incorporated by reference in its entirety.


Despite this and other examples, a need remains for improved medical devices, including implantable valve devices, that include an expandable support frame.


BRIEF OVERVIEW OF EXAMPLE EMBODIMENTS

Various example support frames and medical devices are described and illustrated herein.


An example support frame comprises a first circumferential serpentine path; a second circumferential serpentine path; a first connector segment joining the first and second serpentine paths, the first connector segment comprising substantially parallel first and second struts; a second connector segment disposed substantially opposite the first connector segment with respect to the longitudinal axis of the support frame and joining the first and second serpentine paths, the second connector segment comprising substantially parallel third and fourth struts; a third connector segment disposed circumferentially adjacent the first and second connector segments and joining the first and second serpentine paths; a fourth connector segment disposed substantially opposite the third connector segment and joining the first and second serpentine paths; a first connector strut extending between and joining the first and third connector segments; and a second connector strut extending between and joining the second and third connector segments.


An example medical device comprises an expandable support frame having a longitudinal axis, an outer circumference, an unexpanded configuration, and an expanded configuration with an expanded configuration radius extending from the longitudinal axis to the outer circumference; a first leaflet attached to the support frame along a first attachment pathway, the first leaflet having a first inner surface that defines a domed radius equal to or less than the expanded configuration radius when the support frame is in the expanded configuration; and a second leaflet attached to the support frame along a second attachment pathway, the second leaflet having a second inner surface that defines a second domed radius equal to or less than the expanded configuration radius when the support frame is in the expanded configuration.


Another example medical device comprises an expandable support frame having a longitudinal axis, an outer circumference, an unexpanded configuration, and an expanded configuration with an expanded configuration radius extending from the longitudinal axis to the outer circumference. For this example medical device, the expandable support frame comprises a first circumferential serpentine path; a second circumferential serpentine path; a first connector segment joining the first and second serpentine paths, the first connector segment comprising substantially parallel first and second struts; a second connector segment disposed substantially opposite the first connector segment with respect to said longitudinal axis and joining the first and second serpentine paths, the second connector segment comprising substantially parallel third and fourth struts; a third connector segment disposed circumferentially adjacent the first and second connector segments and joining the first and second serpentine paths; a fourth connector segment disposed substantially opposite the third connector segment and joining the first and second serpentine paths; a first connector strut extending between and joining the first and third connector segments; and a second connector strut extending between and joining the second and third connector segments. This example medical device includes a leaflet attached to the support frame along an attachment pathway extending along the first and second connector struts and along a portion of the first connector segment and a portion of the second connector segment, the leaflet having an inner surface that defines a domed radius equal to or less than the expanded configuration radius when the support frame is in the expanded configuration. The domed radius can be any suitable domed radius, including a domed radius that is between about ⅛th the expanded configuration radius and the expanded configuration radius, a domed radius that is between about ¼th the expanded configuration radius and about ¾th the expanded configuration radius, and a domed radius that is about ¼th the expanded configuration radius.


Another example medical device is similar to the example medical device described above, but also includes a second leaflet attached to the support frame along a second attachment pathway extending along the third and fourth connector struts and along a portion of the first connector segment and a portion of the second connector segment. Similar to the first leaflet, the second leaflet can have a domed radius equal to or less than the expanded configuration radius when the support frame is in the expanded configuration. For the second leaflet, the domed radius can be any suitable domed radius, including a domed radius that is between about ⅛th the expanded configuration radius and the expanded configuration radius, a domed radius that is between about ¼th the expanded configuration radius and about ¾th the expanded configuration radius, and a domed radius that is about ¼th the expanded configuration radius.


In another example medical device having first and second leaflets, as briefly described above, the first and second leaflets have domed radii that are substantially equal. In another example medical device having first and second leaflets, as briefly summarized above, the first and second leaflets have domed radii that are equal.


Additional understanding of the inventive support frames and medical devices can be obtained with review of the detailed description, below, and the appended drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of a first example support frame.



FIG. 2 another perspective view of the first example support frame, rotated ninety degrees from the view illustrated in FIG. 1.



FIG. 3 is a side view of a second example support frame.



FIG. 4 is another side view of the second example support frame, rotated ninety degrees from the view illustrated in FIG. 3.



FIG. 5 is a flat plan view of the support frame illustrated in FIGS. 3 and 4.



FIG. 6 is a side view of a third example support frame.



FIG. 6A is a partial side view of an alternate support frame.



FIG. 6B is a partial side view of another alternate support frame.



FIG. 7 is another side view of the third example support frame, rotated ninety degrees from the view illustrated in FIG. 6.



FIG. 8 is a perspective view of a first example medical device.



FIG. 9 is a side view of a second example medical device.



FIG. 10 is another side view of the second example medical device, rotated ninety degrees from the view illustrated in FIG. 9.



FIG. 11 is a side view of a third example medical device.



FIG. 12 is another side view of the third example medical device, rotated ninety degrees from the view illustrated in FIG. 11.





DETAILED DESCRIPTION OF ILLUSTRATED EXAMPLE EMBODIMENTS

The following detailed description and the appended drawings describe and illustrate various example support frames and medical devices that are embodiments of the invention. The description and drawings are exemplary in nature and are provided to enable one skilled in the art to make and use one or more support frames or medical devices as an embodiment of the invention. The description and drawings are not intended to limit the scope of the claims in any manner.


Inventive intraluminal support frames and medical devices are described. The support frames are useful in the making of intraluminal medical devices, including the medical devices described herein. The support frames may also be useful as medical devices themselves, such as intraluminal stents. The medical devices can be used in any suitable intraluminal environment and to achieve any desired treatment effect in an animal, including human and non-human animals. For example, some of the example medical devices are useful for regulating fluid flow through a body vessel of a patient. As such, the medical devices can be used as valve devices. The medical devices also may be useful for other intraluminal purposes.


Support Frames



FIGS. 1 and 2 illustrate a first example support frame 100.


The support frame 100 is an expandable support frame comprising proximal 102 and distal 104 portions connected by various connector segments 106, 108, 110, 112. The proximal portion 102 defines a first serpentine path 114 that extends around the circumference of the support frame 100. The distal portion 104 defines a second serpentine path 116 that also extends around the circumference of the support frame 100. The first serpentine path 114 includes pairs of straight strut portions 118 and bends 120, each of which is disposed between and connected to a circumferentially adjacent pair of the connector segments 106, 108, 110, 112. The second serpentine path 116 includes curvilinear struts 122, 124, 126, 128. Similar to the first serpentine path 114, each of the curvilinear struts 122, 124, 126, 128 is disposed between and connected to a circumferentially adjacent pair of the connector segments 106, 108, 110, 112. Thus, each serpentine path 114, 116 is joined to connector segments 106, 108, 110, 112.


In the illustrated embodiment, each of the connector segments 106, 108, 110, 112 includes first and second straight struts, designated by the corresponding reference number along with a or b, e.g., 110a, 110b, that are disposed parallel to each other. For each of the connector segments 106, 108, 110, 112, the straight struts are connected to each other by to curvilinear struts, designated by the corresponding reference number along with c or d, e.g., 110c, 110d. This arrangement of struts in the connector segments 106, 108, 110, 112 is considered advantageous at least because it provides a degree of structural redundancy and gives a secondary attachment point for associated materials and/or components in medical devices that include the support frame 100. In the illustrated embodiment, each of connector segments 106, 108, 110, 112 is disposed substantially on the circumferential plane of the support frame 100. It is noted, though, that one or more of the connector segments in a support frame according to a particular embodiment can be disposed entirely or partially outside of the circumferential plane of the support frame 100. For example, one or more connector segments may include a bend or curve that projects outwardly with respect to a longitudinal axis of the support frame. Connector segments with these structural features may be advantageous when additional surface area for contact with a wall of a body vessel and/or formation of an artificial sinus is desired, for example.


The support frame 100 illustrated in FIGS. 1 and 2 has four connector segments 106, 108, 110, 112. Pairs of these connector segments are disposed substantially opposite one another with respect to a longitudinal axis a of the support frame 100. Thus, connector segments 106 and 108 are disposed substantially opposite each other with respect to longitudinal axis a, and connector segments 110 and 112 are disposed substantially opposite each other with respect to longitudinal axis a. As a result, connector segments 106, 108, 110, 112 are distributed on the circumference of the support frame 100 such that each connector segment 106, 108, 110, 112 is positioned approximately equidistantly from two other connector segments 106, 108, 110, 112 along the circumference. It is noted, though, that, in all embodiments that include more than one connector segment, the connector segments can be distributed on the circumference of the support frame in any suitable manner. The illustrated distributions are merely examples of suitable distributions.


While the support frame 100 illustrated in FIGS. 1 and 2 includes four connector segments 106, 108, 110, 112, a support frame according to a particular embodiment can include any suitable number of connector segments. A skilled artisan will be able to determine an appropriate number of connector segments for a particular support frame based on various considerations, including the nature and size of the body vessel into which the support frame, or a medical device containing the support frame, is intended to be implanted and the nature of any materials and/or additional components that will be attached to the support frame in the fabrication of a medical device. When additional rigidity is desired, a greater number of connector segments can be included. When less is desired, one, two or three connector segments can be included. Furthermore, additional or fewer connector segments can be included to accommodate other materials and/or elements of a medical device in which the support frame is used. For example, the use of one, two or three connector segments may be advantageous in valve devices in which contact between a valve leaflet and a vessel wall is desirable.


In the illustrated embodiment, each of the curvilinear struts 122, 124, 126, 128 extends between and joins two of the connector segments 106, 108, 110, 112. For example, as best illustrated in FIG. 1, curvilinear strut 122 extends between and joins connector segments 106 and 110. Specifically, curvilinear strut 122 is connected to one curvilinear strut 110d of connector segment 110 and one curvilinear strut 106d of connector segment 106. Similarly, curvilinear strut 124 extends between and joins connector segments 108 and 110. Specifically, curvilinear strut 124 is connected to one curvilinear strut 110d of connector segment 110 and one curvilinear strut 108d of connector segment 108. As best illustrated in FIG. 2, curvilinear strut 126 extends between and joins connector segments 108 and 112. Thus, curvilinear strut 126 is connected to one curvilinear strut 118d of connector segment 108 and one curvilinear strut 112d of connector segment 112. While not visible in the FIGS., curvilinear strut 128 extends between and joins connector segments 112 and 106.


Inclusion of the curvilinear struts at only the distal end 104 of the support frame 100 provides directionality to the structure of the support frame 100, which is considered advantageous at least because it facilitates fabrication of medical devices that include the support frame 100. It is noted, though, that one or more curvilinear struts can be included on the proximal end, or at any other desirable location, of a support frame according to a particular embodiment.


Each curvilinear strut 122, 124, 126, 128 can have any suitable curvilinear configuration. A skilled artisan will be able to determine an appropriate configuration for a support frame according to a particular embodiment based on various considerations, including the nature of the body vessel within which the support frame is intended to be used, and the nature, size and configuration of any materials and/or additional elements that are attached to the support frame in the fabrication of a medical device that includes the support frame. Examples of suitable curvilinear configurations include curvilinear forms that define arcs, circular arcs, great arcs, s-curves, and others. Furthermore, in any particular embodiment, each curvilinear strut, if multiple curvilinear struts are included, can have the same or different curvilinear configuration as another of the curvilinear struts in the support frame. In the illustrated example embodiment, each of the curvilinear struts has the same curvilinear configuration. While considered advantageous for this illustrated example, this is merely an example of a suitable configuration and arrangement.


The inventors have determined that curvilinear struts that define circular arcs are particularly advantageous for inclusion in the support frames described herein. For example, each of the curvilinear struts 122, 124, 126, 128 in the embodiment illustrated in FIGS. 1 through 2 defines a circular arc.


For a curvilinear strut that defines an arc that is a circular arc or great arc, the arc can comprise a segment of the circumference of any suitable circle. As a result, the arc can have any suitable radius of curvature. A skilled artisan will be able to select an appropriate radius of curvature for such an arc for a support frame according to a particular embodiment based on various considerations, such as the nature and size of the body vessel within which the support frame is to be implanted, the number of curvilinear struts included in the support frame, and the nature, size and/or configuration of any additional material or elements included in a medical device within which the support frame is used.


The inventors have determined that a radius of curvature that is based on the radius of the circumference of the support frame in its expanded configuration provides desirable structural properties. For these structural measurements, the circumference of the support frame is a circumference of a transverse cross-section of the support frame with respect to the longitudinal axis of the support frame. The radius can be measured to either an inner or an outer circumferential surface, or a hypothetical circumferential surface by extension of an actual surface, of the support frame. For example, inclusion of one or more curvilinear struts that define an arc having a radius of curvature that is between about 1/16th the radius of the circumference of the support frame in its expanded configuration and about 1× the radius of the circumference of the support frame in its expanded configuration is suitable. Additional examples of suitable radii of curvature for curvilinear struts include radii of curvature between about ⅛th the radius of the circumference of the support frame in its expanded configuration and about 1× the radius of the circumference of the support frame in its expanded configuration is suitable, radii of curvature between about ¼th and about ¾th the radius of the circumference of the support frame in its expanded configuration, and a radius that is about ½ the radius of the circumference of the support frame in its expanded configuration.


In the embodiment illustrated in FIGS. 1 and 2, the support frame 100 includes four curvilinear struts 122, 124, 126, 128, each of which defines an arc having a radius of curvature r that is about ½ the radius R of the circumference of the support frame in its expanded configuration. The inventors have determined that this configuration and number of curvilinear struts 122, 124, 126, 128 is advantageous for inclusion on support frames according to particular embodiments at least because of the beneficial structural properties provided by the arrangement. Furthermore, as described in more detail below, the inventors have determined that this configuration and number of curvilinear struts 122, 124, 126, 128 is advantageous for inclusion in medical devices according to particular embodiments at least because of the attachment pathways defined by the curvilinear struts 122, 124, 126, 128.


In the illustrated embodiment, support frame 100 includes first 140 and second 142 support struts, each of which extends between and is connected to two of the curvilinear struts 122, 124, 126, 128. While considered optional, the inclusion of support struts 140, 142 may provide desirable structural properties for support frames and/or medical devices according to particular embodiments. If included, the support struts can have any suitable size and configuration. For example, the support struts can comprise straight struts or curvilinear struts. As illustrated in FIGS. 1 and 2, the support struts 140, 142 can comprise parabolic-shaped struts. Also, if included, the support struts can extend from the respective curvilinear struts at any suitable location on each of the curvilinear struts joined by the support strut. For example, as best illustrated in FIG. 1, support strut 140 extends from a point proximal to the curve defined by each of the joined curvilinear struts 122, 124. The inventors have determined that this positioning is advantageous at least because it provides desirable structural properties while not significantly interfering with the attachment pathway defined by the support frame 100 when the support frame 100 is used within a medical device and an additional material and/or additional element is attached to the curvilinear struts 122, 124 along the attachment pathway, as described below.


In all embodiments, the support frame advantageously comprises an expandable support frame having radially compressed and radially expanded configurations. Such a support frame can be implanted at a point of treatment within a body vessel by minimally invasive techniques, such as delivery and deployment with a catheter sized and conFIG.d for navigation within the body vessel. It is noted, though, that support frames and medical devices according to embodiments of the invention, regardless of the type and/or nature of the support frame, can be implanted by other techniques, including surgical techniques.


In all embodiments, the support frame can provide a stenting function, i.e., exert a radially outward force on the interior wall of a vessel in which the support frame, or medical device including the support frame, is implanted. By including a support frame that exerts such a force, a medical device according to the invention can provide multiple functions, such as a stenting and a valving function, at a point of treatment within a body vessel, which may be desirable in certain situations, such as when a degree of vessel stenosis, occlusion, and/or weakening is present.


Support frames according to particular embodiments can include additional structural elements, such as additional struts and bends. The inclusion of additional struts and/or bends may be desirable, for example, in support frames and medical devices intended for implantation at locations in the body where lower radial force on the tissue is desired. For these embodiments, the inclusion of additional struts and/or bends can distribute the radial force of the support frame across more structural elements, thereby reducing the radial force exerted by a particular portion of the support frame against tissue at a point of treatment. A support frame according to an embodiment can include conventional structural features that facilitate anchoring of the support frame at a point of treatment within a body vessel, such as barbs and/or microbarbs, and structural features, such as radiopaque markers, that facilitate visualization of the support frame in conventional or other medical visualization techniques, such as radiography, fluoroscopy, and other techniques. Furthermore, a support frame according to an embodiment can include structural features, such as eyelets, barbs, fillets and other suitable structures, that provide attachment points for grafts and other materials.


In all embodiments, the support frame can be self-expandable or can require an input of force to affect expansion, such as a balloon expandable support frame. Each type of support frame has advantages and for any given application, one type may be more desirable than other types based on a variety of considerations. For example, in the peripheral vasculature, vessels are generally more compliant and typically experience dramatic changes in their cross-sectional shape during routine activity. Support frames and medical devices for implantation in the peripheral vasculature should retain a degree of flexibility to accommodate these changes of the vasculature. Accordingly, support frames and medical devices according to the invention intended for implantation in the peripheral vasculature, such as valve devices, advantageously include a self-expandable support frame.


In all embodiments, the support frames can be made from any suitable material and a skilled artisan will be able to select an appropriate material for use in a support frame according to a particular embodiment based on various considerations, including any desired flexibility and visualization characteristics. The material selected for a support frame according to a particular embodiment need only be biocompatible or be able to be made biocompatible. Examples of suitable materials include, without limitation, stainless steel, nickel titanium (NiTi) alloys, e.g., Nitinol, other shape memory and/or superelastic materials, molybdenum alloys, tantalum alloys, titanium alloys, precious metal alloys, nickel chromium alloys, cobalt chromium alloys, nickel cobalt chromium alloys, nickel cobalt chromium molybdenum alloys, nickel titanium chromium alloys, linear elastic Nitinol wires, polymeric materials, and composite materials. Also, absorbable and bioremodellable materials can be used. As used herein, the term “absorbable” refers to the ability of a material to degrade and to be absorbed into a tissue and/or body fluid upon contact with the tissue and/or body fluid. A number of absorbable materials are known in the art, and any suitable absorbable material can be used. Examples of suitable types of absorbable materials include absorbable homopolymers, copolymers, or blends of absorbable polymers. Specific examples of suitable absorbable materials include poly-alpha hydroxy acids such as polylactic acid, polylactide, polyglycolic acid (PGA), or polyglycolide; trimethlyene carbonate; polycaprolactone; poly-beta hydroxy acids such as polyhydroxybutyrate or polyhydroxyvalerate; or other polymers such as polyphosphazines, polyorganophosphazines, polyanhydrides, polyesteramides, polyorthoesters, polyethylene oxide, polyester-ethers (e.g., polydioxanone) or polyamino acids (e.g., poly-L-glutamic acid or poly-L-lysine). There are also a number of naturally derived absorbable polymers that may be suitable, including modified polysaccharides, such as cellulose, chitin, and dextran, and modified proteins, such as fibrin and casein.


Stainless steel and nitinol are currently considered desirable materials for use in the support frame due at least to their biocompatibility, shapeability, and well-characterized nature. Also, cold drawn cobalt chromium alloys, such as ASTM F562 and ASTM F1058 (commercial examples of which include MP35N™ and Elgiloy™, both of which are available from Fort Wayne Metals, Fort Wayne, Ind.; MP35N is a registered trademark of SPS Technologies, Inc. Jenkintown, Pa., USA); Elgiloy is a registered trademark of Combined Metals of Chicago LLC (Elk Grove Village, Ill., USA)), are currently considered advantageous materials for the support frames at least because they are non-magnetic materials that provide beneficial magnetic resonance imaging (MRI) compatibility and avoid MRI artifacts typically associated with some other materials, such as stainless steel.


The support frames can be fabricated in any suitable manner and by any suitable technique. Skilled artisans will be able to select an appropriate manner and/or technique for fabricating a support frame according to a particular embodiment based on various considerations, including the nature of the material from which the support frame is being fabricated. Examples of suitable techniques include forming the support frame from wire, such as by wrapping a suitable wire around a suitable mandrel, by cutting the support frame from a tubular section of an appropriate material, such as by laser-cutting the support frame from a metal tubular member, and by forming the desired structure of the support frame in sheet form, such as by vapor deposition or other suitable technique, configuring the sheet into tubular form, such as by rolling or other suitable technique, and fixing the support frame in tubular form, such as by laser-welding or other suitable technique.



FIGS. 3 through 5 illustrate a second exemplary support frame 200.


The support frame 200 of this embodiment is similar to support frame 100 illustrated in FIGS. 1 and 2 and described above, except as detailed below. Thus, support frame 200 is an expandable support frame comprising proximal 202 and distal 204 portions connected by various connector segments 206, 208, 210, 212. The proximal portion 202 defines a first serpentine path 214 that extends around the circumference of the support frame 200. The distal portion 204 defines a second serpentine path 216 that also extends around the circumference of the support frame 200. The first serpentine path 214 includes straight strut portions 218 and bends 220. Each serpentine path 214, 216 is joined to connector segments 206, 208, 210, 212.


Similar to the first exemplary embodiment, connector segments 206 and 208 are disposed substantially opposite each other with respect to longitudinal axis a1, and connector segments 210 and 212 are disposed substantially opposite each other with respect to longitudinal axis a1. The support frame 200 includes only two connector segments 210, 212 that each include first and second struts, designated by the corresponding reference number along with a or b, e.g., 210a, 210b. Remaining connector segments 206, 208 each include only a single strut. This configuration is considered advantageous for support frames and medical devices in which a reduction in the overall amount of surface area of the support frame is desirable.


Also, the first 210a and second 210b struts of the first connector segment 210 are disposed at a slight angle with respect to each other and longitudinal axis a1, placing the struts 210a, 210b in a skewed arrangement with respect to each other. A parallel or substantially parallel arrangement of the struts that comprise a particular connector segment is considered advantageous, but a skewed arrangement, such as the arrangement illustrated in FIG. 3, can be used if desired. In this embodiment, the first strut 210a defines first 250a and second 250b eyelets. Similarly, the second strut 212b defines first 252a and second 252b eyelets. Each of the eyelets 250a, 250b, 252a, 252b is a ring-shaped structure defining an opening. As best illustrated in FIG. 3, the first eyelets 250a, 252a are disposed on the struts 210a, 210b such that the center of each eyelet 250a, 252a is positioned on a transverse axis of the support frame 200 that intersects the connector segment 210 at a point that is about ¼th of the height h1 of the connector segment 210. The second eyelets 250b, 252b are disposed on the struts 210a, 210b such that the center of each eyelet 250b, 252b is positioned on a transverse axis of the support frame 200 that intersects the connector segment 210 at a point that is about ½ of the height h1 of the connector segment 210. The inclusion of the eyelets 250a, 250b, 252a, 252b at these positions is considered advantageous at least because they provide attachment points at these positions for materials or additional elements included in medical devices that include the support frame 200, which can provide beneficial performance characteristics. If included, the eyelets can provide other and/or additional functional properties, also. For example, one or more eyelets can provide a structure for engagement by a suitable loading tool for placing a support frame or medical device within a delivery apparatus, such as a catheter. One or more eyelets can also be included to provide a structure for engagement by a suitable tool for withdrawing a support frame or medical device from a storage chamber, such as a hydration container within which a medical device is stored.


While the example support frame 200 includes four eyelets 250a, 250b, 252a, 252b, any suitable number of eyelets can be included in a support frame according to a particular embodiment. Furthermore, the each of the eyelets included in a support frame according to a particular embodiment can be placed at any suitable position on the connector segments for that support frame. Furthermore, the eyelet or eyelet on one straight strut in a connector segment can be positioned at the same or different position, relative to the height of the respective connector segment, as the eyelet or eyelets on another straight strut in a connector segment. A skilled artisan will be able to select an appropriate number of eyelets, an appropriate position for the eyelet or eyelets on the struts of a connector segment, and the relative distribution of the eyelet or eyelets on the straight struts of a connector segment in a support frame according to a particular embodiment based on various considerations, including any desired attachment points for an additional element, such as a graft or leaflet, that will be attached to the support frame, such as in the making of a medical device.


Also in this embodiment, the support frame 200 includes centering struts 244, 246, each of which extends in a proximal and radially outward direction from one of the straight strut portions 218 of the first serpentine path 214. The inventors have determined that the inclusion of centering struts 244, 246 provides beneficial deployment and positioning properties. For example, upon deployment in a body vessel, centering struts 244, 246 provide additional contact with the wall of the body vessel at the proximal portion 202 of the support frame 200, which can prevent or minimize tilting of the support frame 200 with respect to the longitudinal axes of the support frame 200 and the body vessel. If included, the centering struts can have any suitable size and configuration. For example, the centering struts can comprise straight struts, angled struts, a combination of straight struts and bends, as in the illustrated embodiment, or additional curvilinear struts. These struts, if included, can also provide a desirable location for placement of visualization makers, either as a structure fully or partially formed by these struts or as a structure attached to these struts.


In this embodiment, a series of connector struts 260, 262, 264, 266 extend between and join pairs of the connector segments 206, 208, 210, 212. Each of the connector struts 260, 262, 264, 266 extends between one of the connector segments 210, 212 that includes two struts, such as struts 210a and 210b, and one of the connector segments that includes only a single strut, such as connector segment 208. Thus, for example, connector strut 260 extends between and joins connector segments 210 and 206. Similarly, connector strut 262 extends between and joins connector segments 210 and 208.


Each of the connector struts 260, 262, 264, 266 lies on a plane that is disposed at an angle γ to a plane t1 that orthogonally transects the longitudinal axis a1 and includes the terminal structures of the distal portion 204 of the support frame 200. Each connector strut 260, 262, 264, 266 can lie on a plane disposed at any suitable angle. A skilled artisan will be able to determine an appropriate angle for each connector strut in a support frame according to a particular embodiment based on various considerations, including the nature of the body vessel within which the support frame is intended to be used, and the nature, size and configuration of any materials and/or additional elements that are attached to the support frame in the fabrication of a medical device that includes the support frame. Examples of suitable angles include angles between about 30° and about 50°, angles between about 30° and about 40°, and an angle that is about 35°.


While each of the connector struts 260, 262, 264, 266 in the illustrated embodiment is disposed at the same or substantially the same angle γ when the support frame is in its expanded configuration, different angles can be used for some or all of the connector struts. While considered advantageous, the illustrated configuration is merely an example of a suitable configuration.



FIGS. 6 and 7 illustrate a third example support frame 300.


The support frame 300 of this embodiment is similar to support frame 200 illustrated in FIGS. 3 through 5 and described above, except as detailed below. Thus, support frame 300 is an expandable support frame comprising proximal 302 and distal 304 portions connected by various connector segments 306, 308, 310, 312. The proximal portion 302 defines a first serpentine path 314 that extends around the circumference of the support frame 300. The distal portion 304 defines a second serpentine path 316 that also extends around the circumference of the support frame 300. The first serpentine path 314 includes straight strut portions 318 and bends 320. Each serpentine path 314, 316 is joined to connector segments 306, 308, 310, 312.


Connector segments 306 and 308 are disposed substantially opposite each other with respect to longitudinal axis a1, and connector segments 310 and 312 are disposed substantially opposite each other with respect to longitudinal axis a1. Similar to the embodiment illustrated in FIGS. 3 through 5 and illustrated above, the support frame 300 includes only two connector segments 310, 312 that each include first and second struts, designated by the corresponding reference number along with a or b, e.g., 310a, 310b. Remaining connector segments 306, 308 each include only a single strut.


In this embodiment, the pair of struts that define each of connector segments 310 and 312 are disposed substantially parallel to each other. Also, each of the struts in the pair of struts that define each of connector segments 310 and 312 defines a single eyelet. Thus, as best illustrated in FIG. 6, the first strut 310a of connector segment 310 defines eyelet 350 and the second strut 310b defines eyelet 352. Each of the eyelets 350, 352 is a ring-shaped structure defining an opening. In this embodiment, each of the eyelets 350, 352 is disposed on the respective strut 310a, 310b such that the center of each eyelet 350, 352 is positioned on a transverse axis of the support frame 300 that orthogonally intersects the connector segment 310 at a point that is about ¼th of the height h1 of the connector segment 310. It is noted that, while the illustrated eyelets 350, 352 pass through the entire thickness of the respective struts 310a, 310b from one surface to an opposing surface, any other suitable structure can be used, such as passageways that pass through a partial thickness of the respective strut and/or blind openings.


In this embodiment, a series of connector struts 360, 362, 364, 366 extend between and join pairs of the connector segments 306, 308, 310, 312. Each of the connector struts 360, 362, 364, 366 extends between one of the connector segments 310, 312 that includes two struts, such as struts 310a and 310b, and one of the connector segments that includes only a single strut, such as connector segment 308. Thus, for example, connector strut 360 extends between and joins connector segments 310 and 306. Similarly, connector strut 362 extends between and joins connector segments 310 and 308.


In this embodiment, each of the connector struts 360, 362, 364, 366 is a curvilinear strut that includes a straight portion, designated by the corresponding reference number along with a. The straight portion 360a, 362a, 364a, 366a of each of the connector struts 360, 362, 364, 366 lies on a plane that is disposed at an angle γ to a plane that orthogonally transects the longitudinal axis a1 and includes the terminal structures of the distal portion 304 of the support frame 300. Each connector strut 360, 362, 364, 366 can lie on a plane disposed with its respective straight portion 360a, 362a, 364a, 366a at any suitable angle. A skilled artisan will be able to determine an appropriate angle for each connector strut in a support frame according to a particular embodiment based on various considerations, including the nature of the body vessel within which the support frame is intended to be used, and the nature, size and configuration of any materials and/or additional elements that are attached to the support frame in the fabrication of a medical device that includes the support frame. Examples of suitable angles include angles between about 30° and about 50°, angles between about 30° and about 40°, and an angle that is about 35°.


While each of the connector struts 360, 362, 364, 366 in the illustrated embodiment is disposed with the respective straight portion 360a, 362a, 364a, 366a at the same or substantially the same angle γ when the support frame is in its expanded configuration, different angles can be used for some or all of the connector struts. While considered advantageous, the illustrated configuration is merely an example of a suitable configuration.


Each of FIGS. 6A and 6B illustrate a connector segment 310′ of an alternative support frame. In each figure, the connector segment 310′ includes alternative structure for the eyelets 350, 352 illustrated in FIG. 6. In these alternative embodiments, bars 350′, 352′ are included instead of the eyelets. The purpose of the bars 350′, 352′ is the same as the eyelets 350, 352 illustrated in FIG. 6, but the structure is different. Instead of defining an opening, each bar 350′, 352′ is a straight member or substantially straight member that extends between the pair of struts 310a′, 310b′ that define a connector segments 310′. If included in a support frame or medical device according to a particular embodiment, any suitable number of bars can be included and each of the included bars can be placed in any suitable position. In each of FIGS. 6A and 6B, two bars 350′, 352′ are included, but each figure illustrates a different relative positioning for the bars 350′, 352′.


If included, the bars 350′, 352′ can be positioned in a similar manner as the eyelets 350, 352 in the support frame 300 illustrated in FIG. 6. Thus, as illustrated in FIGS. 6A and 6B, one bar 350′ is disposed on the respective struts 310a′, 310b′ such that the lengthwise axis of the bar 350′ is positioned on a transverse axis of the support frame 300′ that orthogonally intersects the connector segment 310′ at a point that is about ¼th of the height h1′ of the connector segment 310′. This height is represented as h2′ in FIGS. 6A and 6B.


Inclusion of additional bars is optional. If included, any additional bars can be positioned at any suitable location on the connector segment 310′. FIGS. 6A and 6B illustrate example positioning for a second bar 352′. In FIG. 6A, a second bar 352′ is disposed on the respective struts 310a′, 310b′ such that the lengthwise axis of the bar 352′ is positioned on a transverse axis of the support frame 300′ that orthogonally intersects the connector segment 310′ at a point that is about ½ of the height h1′ of the connector segment 310′. This height is represented as h3′ in FIG. 6A. In this arrangement, the second bar 352′ is largely independent of the first bar 350′ and provides a second, independent point of attachment for additional materials, such as a valve leaflet or graft material.


In FIG. 6B, a second bar 352′ is disposed on the respective struts 310a′, 310b′ such that the bar is associated closely with the first bar 350′. In this embodiment, a hypothetical line extending between the pair of struts 310a′, 310b′ that define connector segment 310′ and that is spaced equidistantly from each of the bars 350′, 352′ is positioned on a transverse axis of the support frame 300′ that orthogonally intersects the connector segment 310′ at a point that is about ¼th of the height h1′ of the connector segment 310′. This height is represented as h2′ in FIGS. 6A and 6B. In this arrangement, the second bar 352′ is paired with the first bar 350′ to cooperatively define an opening that provides a point of attachment for additional materials, such as a valve leaflet or graft material.


Medical Devices



FIG. 8 illustrates a first exemplary medical device 400.


The medical device 400 is a valve device that includes the first example support frame 100 illustrated in FIGS. 1 and 2 and first 480 and second 482 leaflets. The first leaflet 480 is attached to the support frame 100 along a first attachment pathway 170 that extends along curvilinear struts 122, 128 and along a portion of connector segments 110, 112. Similarly, the second leaflet 482 is attached to the support frame 100 along a second attachment pathway 172 that extends along curvilinear struts 124, 126 and along a portion of connector segments 110, 112. Each leaflet 480, 482 has a free edge 484, 486 that is not attached to the support frame 100. The free edges 484, 486 cooperatively define valve orifice 488.


The medical device 400 is a valve device that is useful for regulating fluid flow through a body vessel. Each of the leaflets 480, 482 is movable between first and second positions. In the first position, the orifice 488 is open and allows fluid flow through the device 400 in a first direction. In the second position, the free edges 484, 486 of leaflets 480, 482 come together to close the orifice 488 and substantially prevent fluid flow through the device 400 in a second, opposite direction.


Each of the leaflets 480, 482 can have any suitable size, shape and/or configuration. A skilled artisan will be able to select leaflets having appropriate size, shape and configuration properties for a medical device according to a particular embodiment based on various considerations, including any desired performance characteristics of the medical device. The inventors have determined that leaflets that, when attached to a support frame and when the support frame is in an expanded configuration and the leaflets subjected to fluid pressure sufficient to effect closure of the valve orifice, define a domed radius of curvature, i.e., a portion of one surface of the leaflet lies on a portion of a spherical plane or substantially spherical plane, provide desirable performance characteristics for medical devices intended to be used as valve devices, such as prosthetic venous valve devices. In these embodiments, the portion of a spherical plane or substantially spherical plane can comprise a portion of the spherical plane of any suitable sphere. As a result, the portion of a spherical plane or substantially spherical plane can have any suitable radius of curvature. Also in these embodiments, the portion the surface of the leaflet that defines the domed radius can comprise any suitable portion of the leaflet surface, including a central portion that does not contact any struts or other structural members of the associated support frame, a base portion that is positioned at the bottom of a valve pocket formed in the valve device when the valve orifice is closed, or any other suitable portion of the leaflet surface. A skilled artisan will be able to select an appropriate portion of the leaflet surface and an appropriate radius of curvature for a medical device according to a particular embodiment based on various considerations, including the nature and size of the body vessel within which the medical device is to be implanted, and the nature of the material from which the leaflets are formed. Also, it is noted that the domed radii described herein are present in the respective leaflet at least when the leaflet is subjected to fluid pressure sufficient to close the associated valve orifice, such as when the medical device containing the leaflet is exposed to such fluid pressure in vivo or in suitable testing environments, such as in a vessel simulator or a simple fluid container.


The inventors have determined that leaflets defining a domed radius that is based on the radius of the circumference of the support frame in its expanded configuration provides desirable structural properties. For example, inclusion of one or more curvilinear leaflets that define a domed radius having a radius of curvature that is between about ⅛th the radius of the circumference of the support frame in its expanded configuration and about 1× the radius of the circumference of the support frame in its expanded configuration is suitable. Additional examples of suitable radii of curvature include radii of curvature between about ¼th and about ¾th the radius of the circumference of the support frame in its expanded configuration, and a radius that is about ½ the radius of the circumference of the support frame in its expanded configuration.


The exemplary medical device 400 is illustrated with the support frame 100 in an expanded configuration and with the leaflets 480, 482 in the configuration they adopt when subjected to fluid pressure sufficient to effect closure of the valve orifice. As illustrated in the FIG., in this state, each of the leaflets 480, 482 defines a domed radius of curvature r that is about ½ the radius R of the circumference of the support frame 100 in its expanded configuration. The inventors have determined that this configuration of the leaflets 480, 482 is advantageous at least because of the beneficial performance characteristics provided by the arrangement.


It is noted that, while the medical device 400 is illustrated as including support frame 100, any suitable support frame that positions the leaflets 480, 482 in the desired configuration, i.e., with the domed radius, can be used. For example, leaflets can be attached to any of the support frame described and illustrated herein such that the desired configuration is achieved. A skilled artisan will be able to select an appropriate support frame for a medical device according to a particular embodiment based on various considerations, including the nature, size and configuration of the material forming the leaflets.



FIGS. 9 and 10 illustrate a second example medical device 500.


The medical device 500 is a valve device that includes the third exemplary support frame 300 illustrated in FIGS. 6 and 7 and first 580 and second 582 leaflets. The first leaflet 580 is attached to the support frame 300 along a first attachment pathway 370 that extends along connector struts 360, 366 and along a portion of connector segments 310, 312. Similarly, the second leaflet 582 is attached to the support frame 300 along a second attachment pathway 372 that extends along connector struts 362, 364 and along a portion of connector segments 310, 312. Each leaflet 580, 582 has a free edge 584, 586 that is not attached to the support frame 300. The free edges 584, 586 cooperatively define valve orifice 588.


The medical device 500 is a valve device that is useful for regulating fluid flow through a body vessel. Each of the leaflets 580, 582 is movable between first and second positions. In the first position, the orifice 588 is open and allows fluid flow through the device 500 in a first direction. In the second position, the free edges 584, 586 of leaflets 580, 582 come together to close the orifice 588 and substantially prevent fluid flow through the device 500 in a second, opposite direction.


In this embodiment, each attachment pathway 370, 372 extends along a portion of the axial length of connector segment 310 and along a portion of the axial length of connector segment 312. For each attachment pathway 370, 372 and each connector segment 310, 312, the portion of the axial length of the connector segment 310, 312 along which the attachment pathway extends can be any suitable portion of the axial length of the connector segment 310, 312, including the entire axial length of the connector segment 310, 312. For each attachment pathway and each connector segment in a medical device according to a particular embodiment, a skilled artisan will be able to select an appropriate portion of the axial length along which the attachment pathway extends based on various considerations, such as the nature, size and configuration of the leaflets or other material and/or additional elements included in the medical device.


The inventors have determined that a portion of the axial length of the connector segment along which the attachment pathway extends that is between about 1/16th the full axial length of the connector segment and about the full axial length of the connector segment is suitable. Additional examples of suitable portions of the axial length of the connector segments along which the attachment pathways extend include portions of the axial length of the connector segments that are between about ⅛th the full axial length of the connector segment and about ¾th the full axial length of the connector segment, and portions of the axial length of the connector segments that are between about ¼th the full axial length of the connector segment and about ½ the full axial length of the connector segment.


In the embodiment illustrated in FIGS. 9 and 10, each of the attachment pathways 370, 372 extends along a portion of each connector segment 310, 312 that is equal to about ¼th the full axial length of the respective connector segment 310, 312. In this embodiment, the connector segments 310, 312 have approximately equal axial lengths, so the portions of the axial lengths along which the attachment pathways 370, 372 extend are also approximately equal. The inventors have determined that this configuration of the attachment pathways 370, 372 is advantageous for inclusion in medical devices according to particular embodiments at least because it provides desirable performance characteristics.


In any particular embodiment, the attachment pathways, if included, can extend along the same or different portion of the axial length of each connector segment. For example, a medical device according to an embodiment can include a first attachment pathway that extends along approximately equal portions of the axial lengths of first and second connector segments and a second attachment pathway that extends along approximately equal portions of the axial lengths of the first and second connector segments that are different than the portions along which the first attachment pathway extends. Furthermore, a medical device according to an embodiment may include one or more attachment pathways that extends along a portion of the axial length of a first connector segment and along a portion of the axial length of a second connector segment that is less than, equal to, approximately equal to, or greater than the portion of the axial length of the first connector segment.


In the illustrated embodiment, the attachment pathways 370, 372 also extend along connector struts 360, 362, 364, 366 that extend between and join adjacent pairs of connector segments 306, 308, 310, 312. If included, any suitable connector struts can be used in a medical device according to a particular embodiment and a skilled artisan will be able to select appropriate connector struts based on various considerations, including the nature of the material from which the element(s) being attached to the support frame, such as leaflets, is formed. As illustrated in FIGS. 9 and 10, connector struts 360, 362, 364, 366 that each comprise a curvilinear strut that includes a straight portion, designated by the corresponding reference number along with a, are considered suitable. In the illustrated embodiment, the straight portion 360a, 362a, 364a, 366a of each of the connector struts 360, 362, 364, 366 lies on a plane that is disposed at an angle γ2 to a plane that orthogonally transects the longitudinal axis a4 and includes the terminal structures of the distal portion 304 of the support frame 300. Each connector strut 360, 362, 364, 366 can be disposed with its respective straight portion 360a, 362a, 364a, 366a at any suitable angle. A skilled artisan will be able to determine an appropriate angle for each connector strut in a support frame according to a particular embodiment based on various considerations, including the nature of the body vessel within which the support frame is intended to be used, and the nature, size and configuration of any materials and/or additional elements that are attached to the support frame in the fabrication of a medical device that includes the support frame. Examples of suitable angles include angles between about 30° and about 50°, angles between about 30° and about 40°, and an angle that is about 35°.



FIGS. 11 and 12 illustrate a third example medical device 600.


The medical device 600 is a valve device that includes a modified version of the third exemplary support frame 300′ illustrated in FIGS. 6 and 7 and first 680 and second 682 leaflets. The medical device 600 is similar to the second exemplary medical device 500 described above and illustrated in FIGS. 9 and 10, except as detailed below. The first leaflet 680 is attached to the support frame 300′ along a first attachment pathway 370′ that extends along connector struts 360, 366 and along a portion of connector segments 310′, 312′. Similarly, the second leaflet 682 is attached to the support frame 300′ along a second attachment pathway 372′ that extends along connector struts 362, 364 and along a portion of connector segments 310′, 312′. Each leaflet 680, 682 has a free edge 684, 686 that is not attached to the support frame 300. The free edges 684, 686 cooperatively define valve orifice 688.


The medical device 600 is a valve device that is useful for regulating fluid flow through a body vessel. Each of the leaflets 680, 682 is movable between first and second positions. In the first position, the orifice 688 is open and allows fluid flow through the device 600 in a first direction. In the second position, the free edges 684, 686 of leaflets 680, 682 come together to close the orifice 688 and substantially prevent fluid flow through the device 600 in a second, opposite direction.


In this embodiment, support frame 300 includes eyelets 350′, 352′, 354′, 356′. The first 310a′ strut of the first connector segment 310′ defines eyelet 350′. Similarly, the second strut 310b′ of the first connector segment 310′ defines eyelet 354′. Similarly, the first 312a′ and second 312b′ struts of the second connector segment each defines one of remaining eyelets 354′, 356′. Each of the eyelets is a ring-shaped structure defining an opening. As best illustrated in FIG. 11, each of the 350′, 352′, 354′, 356′ is disposed on the respective strut 310a′, 310b′, 312a′, 312b′ of the respective connector segment 310′, 312′ such that the center of each eyelet 350′, 352′, 354′, 356′ is positioned on a transverse axis of the support frame 300′ that intersects the connector segments 310′, 312′ at a point corresponding to a height h4 that is about ½ of the height h5 of the respective connector segment 310′, 312′. The inclusion of the eyelets 350′, 352′, 354′, 356′ at these positions is considered advantageous at least because they provide attachment points at these positions for the leaflets 680, 682, which can provide beneficial performance characteristics.


In this embodiment, the free edge 684, 686 of each leaflet defines a curve. If leaflets having this structure are included, any suitable curve can be used and a skilled artisan will be able to select an appropriate curve or curves based on various considerations, including the nature of the material from which the leaflets are formed. As best illustrated in FIG. 12, a parabolic curve is considered suitable. Indeed, the inventors have determined that a parabolic curve that, when the respective leaflet 682 is attached to the support frame 300, extends inwardly from points 690, 692 on the respective attachment pathway 372 that correspond to a height h4 is about ½ of the height h5 of the respective connector segment 312′ to an apex 694 that is at a point that corresponds to a height h6 that is about ¼th of the height h5 of the respective connector segment 312′, is considered suitable.


If a leaflet having a free edge defining a curve is used, the curve can be formed prior to attaching the leaflet to the support frame, or can be formed following attachment of the leaflet to the support frame, such as by cutting the leaflet to create a free edge defining a desired curve.


In all embodiments, any suitable materials and/or additional elements can be attached to the support frame to form a medical device. A skilled artisan will be able to select an appropriate material for use with a support frame in a medical device according to a particular embodiment based on various considerations, including the intended use and desired function of the medical device. For valve devices, such as the valve device illustrated in FIGS. 9 and 10, each of the leaflets 580, 582 comprises a section of material, such as a sheet, that is attached to the support frame 300 along a respective attachment pathway 370, 372, as described above. The leaflets 580, 582 can be formed of any suitable material, and need only be biocompatible or be able to be made biocompatible. The material can advantageously be formed of a flexible material. Examples of suitable materials for use as leaflets in medical devices that comprise valve devices include natural materials, synthetic materials, and combinations of natural and synthetic materials. Examples of suitable natural materials include extracellular matrix (ECM) materials, such as small intestine submucosa (SIS), and other bioremodelable materials, such as bovine pericardium. Other examples of suitable ECM materials that can be used include stomach submucosa, liver basement membrane, urinary bladder submucosa, tissue mucosa, and dura mater. Other examples of suitable natural materials include renal capsule matrix, abdominal fascia, parenchyma, such as abdominal parenchyma, connective tissue, pulmonary or lung ligament, tissue laminates, and natural valve leaflets with or without adjacent vessel wall. Pleura is also considered a suitable natural material, including visceral pleura. Fixed tissues are also considered suitable, including fixed SIS, fixed pericardium, fixed pulmonary or lung ligament, and any other suitable fixed natural tissue. When fixed tissue is used, any suitable fixation technique and/or procedure can be used, including chemical fixatives, such as aldehydes, e.g., formaldehyde, gluteraldehyde, and formalin, and carbodiimides, such as ethyl dimethylaminopropyl carbodiimide, dicyclohexylcarbodiimide. Physical fixation techniques and/or procedures can also be used, including exposure to heat and/or radiation. Lyophilized preparations and chemically-dried preparations of these natural materials are also considered suitable. Examples of suitable synthetic materials include polymeric materials, such as expanded polytetrafluoroethylene, polyurethane, polyurethane urea, polycarbonate, and polyesters.


Any attached materials can have any suitable size, shape and configuration. For example, valve devices can include one, two or more leaflets that are sheet-like sections of material attached to a support frame according to an embodiment. Another example of a material that can be attached to a support frame according to an embodiment is a tubular structure that is attached around the outer circumference of the support frame. Indeed, a tubular structure and one, two or more leaflets can be attached to a support frame according to an embodiment to form a valve device having an outer sleeve.


In all embodiments including additional material and/or elements attached to the support frame, the additional material and/or elements can be attached to the support frame in any suitable manner and with any suitable structure and/or substance. For example, leaflets can be attached to a support frame in a valve device using sutures, tissue welding, adhesive(s), mechanical attachment(s), a combination of these approaches, and any other suitable structure and/or substance.


In all embodiments including an additional material and/or elements attached to the support frame, the additional material and/or elements can be attached to the support frame in any suitable orientation. A skilled artisan will be able to select a suitable orientation for a particular material or element attached to the support frame in a specific embodiment based on various considerations, including the physical properties of the material or element and any desired properties of the resulting medical device that may be impacted by the orientation of the material or element. For example, for valve devices that include one or more leaflets attached to the support frame, it may be desirable to attach the leaflet or leaflets in a particular orientation based on the ability of the leaflet to stretch in a particular direction. Anisotropic materials may be able to stretch to a greater degree along one axis than along another axis. The inventors have determined that, when attaching an anisotropic material to a support frame to form a medical device, it may be desirable to attach the material in an orientation in which the axis along which the material has a greater ability to stretch is aligned with the longitudinal axis of the support frame if it is desirable to have the leaflet of the medical device form a relatively deeper valve pocket when the medical device is subjected to sufficient fluid pressure to move the leaflet to a closed position. Conversely, the inventors have determined that it may be desirable to attach the material in an orientation in which the axis along which the material has a greater ability to stretch is aligned in a transverse orientation to the longitudinal axis of the support frame if it is desirable to have the leaflet of the medical device form a relatively larger valve orifice when the medical device is subjected to sufficient fluid pressure to move the leaflet to an open position.


For valve devices, the inventors have determined that attaching a leaflet to a support frame described herein while the leaflet is held in an open position can provide desirable performance characteristics to the resulting valve device. Specifically, the inventors have determined that attaching a leaflet to a support frame described herein while the leaflet is held in an open position on a mandrel such that a degree of slack is provided in a portion of the leaflet that will have a domed radius can provide desirable performance characteristics to the resulting valve device.


Furthermore, while the medical devices described and illustrated herein are valve devices, it is noted that other types of medical devices can be made in accordance with the disclosure. For example, a vessel occluder can include a support frame according to an embodiment along with leaflets that are sewn or otherwise attached to each other to permanently close an associated valve orifice or a graft material that lacks an orifice.


The support frames and medical devices can be implanted within a body vessel at a desired point of treatment using conventional minimally-invasive techniques, such as by delivery with an associated catheter, by surgical techniques, or by any other suitable technique for placing a support frame or medical device at a point of treatment within a body vessel.


The foregoing detailed description refers to example support frames and medical devices and includes the best mode for practicing the invention. The description and the appended drawings illustrating the described devices are intended only to provide examples and not to limit the scope of the claims in any manner.

Claims
  • 1. A medical device for regulating fluid flow through a body vessel of a patient, comprising: an expandable support frame having a longitudinal axis, an outer circumference, and an unexpanded configuration, the support frame comprising: a first connector segment having an axial length and comprising substantially parallel first and second struts and a first connecting bar extending between and joining the first and second struts;a second connector segment having an axial length and disposed substantially opposite the first connector segment with respect to said longitudinal axis, the second connector segment comprising substantially parallel third and fourth struts and a second connecting bar extending between and joining the third and fourth struts;a third connector segment disposed circumferentially adjacent the first and second connector segments, the third connector segment being only a single strut;a fourth connector segment disposed substantially opposite the third connector segment with respect to said longitudinal axis; a proximal portion defining a first circumferential serpentine path joined to the first, second, third, and fourth connector segments; anda distal portion defining a second circumferential serpentine path joined to the first, second, third, and fourth connector segments and comprising a first connector strut extending between and joining the first and third connector segments, a second connector strut extending between and joining the second and third connector segments, a third connector strut extending between and joining the first and fourth connector segments, and a fourth connector strut extending between and joining the second and fourth connector segments, each of the first connector strut, the second connector strut, the third connector strut, and the fourth connector strut comprising a curvilinear strut that includes a straight portion;a first leaflet attached to the support frame along an attachment pathway extending along the first and second connector struts and only along a first portion of the first connector segment extending from the distal portion and toward the proximal portion and a first portion of the second connector segment extending from the distal portion and toward the proximal portion, the first leaflet having a first free edge and a first inner surface; anda second leaflet attached to the support frame along a second attachment pathway extending along the third and fourth connector struts and along a second portion of the first connector segment and a second portion of the second connector segment, the second leaflet having a second free edge and a second inner surface;wherein the first and second free edges cooperatively define a valve orifice;wherein the first portion of the first connector segment is between about ⅛th and about ¾th the axial length of the first connector segment;wherein the first portion of the second connector segment is between about ⅛th and about ¾th the axial length of the second connector segment; andwherein the single strut extends from the proximal portion to the first connector strut and the second connector strut.
  • 2. The medical device of claim 1, wherein the first portion of the first connector segment is about ¼th the axial length of the first connector segment.
  • 3. The medical device of claim 2, wherein the first portion of the second connector segment is about ¼th the axial length of the second connector segment.
  • 4. The medical device of claim 3, wherein the first connecting bar is positioned on a first transverse axis of the support frame that orthogonally intersects the first connector segment at a point that is about ¼th the axial length of the first connector segment; and wherein the second connecting bar is positioned on a second transverse axis of the support frame that orthogonally intersects the second connector segment at a point that is about ¼th the axial length of the second connector segment.
  • 5. The medical device of claim 1, further comprising a third connecting bar extending between the first and second struts.
  • 6. The medical device of claim 1, wherein the support frame is free of additional struts between the first connector segment and the third connector segment.
  • 7. The medical device of claim 6, wherein the support frame is free of additional struts between the second connector segment and the third connector segment.
  • 8. The medical device of claim 7, wherein the support frame is free of additional struts between the first connector segment and the fourth connector segment.
  • 9. The medical device of claim 8, wherein the support frame is free of additional struts between the second connector segment and the fourth connector segment.
  • 10. The medical device of claim 1, wherein the first and second leaflets comprise a natural material.
  • 11. The medical device of claim 10, wherein the natural material comprises a bioremodelable material.
  • 12. The medical device of claim 11, wherein the bioremodelable material comprises an extracellular matrix material.
  • 13. The medical device of claim 12, wherein the extracellular matrix material comprises small intestine submucosa.
  • 14. The medical device of claim 12, wherein the extracellular matrix material is selected from the group consisting of stomach submucosa, liver basement membrane, urinary bladder submucosa, tissue mucosa, and dura mater.
  • 15. The medical device of claim 10, wherein the natural material comprises lung ligament.
  • 16. The medical device of claim 10, wherein the natural material comprises visceral pleura.
  • 17. The medical device of claim 10, wherein the natural material comprises fixed tissue.
  • 18. A medical device for regulating fluid flow through a body vessel of a patient, comprising: an expandable support frame having a longitudinal axis, an outer circumference, and an unexpanded configuration, the support frame comprising: a first connector segment having an axial length and comprising substantially parallel first and second struts and a first connecting bar extending between and joining the first and second struts on a first transverse axis that orthogonally intersects the first connector segment at a point that is about ¼th the axial length of the first connector segment;a second connector segment having an axial length and disposed substantially opposite the first connector segment with respect to said longitudinal axis, the second connector segment comprising substantially parallel third and fourth struts and a second connecting bar extending between and joining the third and fourth struts on a second transverse axis that orthogonally intersects the second connector segment at a point that is about ¼th the axial length of the second connector segment;a third connector segment disposed circumferentially adjacent the first and second connector segments;a fourth connector segment disposed substantially opposite the third connector segment with respect to said longitudinal axis;a proximal portion defining a first circumferential serpentine path joined to the first, second, third, and fourth connector segments; anda distal portion defining a second circumferential serpentine path joined to the first, second, third, and fourth connector segments and comprising a first connector strut extending between and joining the first and third connector segments, a second connector strut extending between and joining the second and third connector segments, a third connector strut extending between and joining the first and fourth connector segments, and a fourth connector strut extending between and joining the second and fourth connector segments, each of the first connector strut, the second connector strut, the third connector strut, and the fourth connector strut comprising a curvilinear strut that includes a straight portion;a first leaflet attached to the support frame along an attachment pathway extending along the first and second connector struts and only along a first portion of the first connector segment extending from the distal portion and toward the proximal portion to the first connecting bar and a first portion of the second connector segment extending from the distal portion and toward the proximal portion to the second connecting bar, the first leaflet having a first free edge and a first inner surface; anda second leaflet attached to the support frame along a second attachment pathway extending along the third and fourth connector struts and along a second portion of the first connector segment to the first connecting bar and a second portion of the second connector segment to the second connecting bar, the second leaflet having a second free edge and a second inner surface;wherein the first and second free edges cooperatively define a valve orifice;wherein the first portion of the first connector segment is about ¼th the axial length of the first connector segment; andwherein the first portion of the second connector segment is about ¼th the axial length of the second connector segment.
  • 19. The medical device of claim 18, wherein the third connector segment is only a single strut extending from the proximal portion to the first connector strut and the second connector strut.
  • 20. A medical device for regulating fluid flow through a body vessel of a patient, comprising: an expandable support frame having a longitudinal axis, an outer circumference, and an unexpanded configuration, the support frame comprising: a first connector segment having an axial length and comprising substantially parallel first and second struts and a first connecting bar extending between and joining the first and second struts on a first transverse axis that orthogonally intersects the first connector segment at a point that is about ¼th the axial length of the first connector segment;a second connector segment having an axial length and disposed substantially opposite the first connector segment with respect to said longitudinal axis, the second connector segment comprising substantially parallel third and fourth struts and a second connecting bar extending between and joining the third and fourth struts on a second transverse axis that orthogonally intersects the second connector segment at a point that is about ¼th the axial length of the second connector segment;a third connector segment disposed circumferentially adjacent the first and second connector segments;a fourth connector segment disposed substantially opposite the third connector segment with respect to said longitudinal axis;a proximal portion defining a first circumferential serpentine path joined to the first, second, third, and fourth connector segments; anda distal portion defining a second circumferential serpentine path joined to the first, second, third, and fourth connector segments and comprising a first connector strut extending between and joining the first and third connector segments, a second connector strut extending between and joining the second and third connector segments, a third connector strut extending between and joining the first and fourth connector segments, and a fourth connector strut extending between and joining the second and fourth connector segments, each of the first connector strut, the second connector strut, the third connector strut, and the fourth connector strut comprising a curvilinear strut that includes a straight portion;a first leaflet attached to the support frame along an attachment pathway extending along the first and second connector struts and only along a first portion of the first connector segment extending from the distal portion and toward the proximal portion to the first connecting bar and a first portion of the second connector segment extending from the distal portion and toward the proximal portion to the second connecting bar, the first leaflet comprising fixed natural tissue comprising visceral pleura and having a first free edge and a first inner surface; anda second leaflet attached to the support frame along a second attachment pathway extending along the third and fourth connector struts and along a second portion of the first connector segment to the first connecting bar and a second portion of the second connector segment to the second connecting bar, the second leaflet comprising fixed natural tissue comprising visceral pleura and having a second free edge and a second inner surface;wherein the first and second free edges cooperatively define a valve orifice;wherein the first portion of the first connector segment is about ¼th the axial length of the first connector segment; andwherein the first portion of the second connector segment is about ¼th the axial length of the second connector segment.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/176,364, filed on Feb. 10, 2014, and which claims the benefit of U.S. Provisional Application No. 61/763,107, filed on Feb. 11, 2013. The entire contents of each of these related applications is incorporated into this disclosure by reference.

US Referenced Citations (1242)
Number Name Date Kind
3012882 Muldawer et al. Dec 1961 A
3014104 Cobine et al. Dec 1961 A
3174851 Buehler et al. Dec 1961 A
3063967 Schultz Nov 1962 A
3169945 Hostettler et al. Feb 1965 A
3391126 Baggett et al. Jul 1968 A
3464065 Cromie Sep 1969 A
3583391 Cox et al. Jun 1971 A
3589392 Meyer Jun 1971 A
3645941 Snapp et al. Feb 1972 A
3710744 Goodenough et al. Jan 1973 A
3736598 Bellhouse et al. Jun 1973 A
3737919 Child Jun 1973 A
3772137 Tolliver Nov 1973 A
3912692 Casey et al. Oct 1975 A
3942532 Hunter et al. Mar 1976 A
3953566 Gore Apr 1976 A
3983581 Angell et al. Oct 1976 A
4052988 Doddi et al. Oct 1977 A
4076807 Trinh et al. Feb 1978 A
4093061 Horak Jun 1978 A
4106129 Carpentier et al. Aug 1978 A
4218782 Rygg Aug 1980 A
4222126 Boretos et al. Sep 1980 A
4243775 Rosensaft et al. Jan 1981 A
4274292 Angell Jan 1981 A
4272854 Bokros Jun 1981 A
4275469 Gabbay Jun 1981 A
4297749 Davis et al. Nov 1981 A
4300565 Rosensaft et al. Nov 1981 A
4328592 Klawitter May 1982 A
4340977 Brownlee et al. Jul 1982 A
4345340 Rosen Aug 1982 A
4350492 Wright et al. Sep 1982 A
4364126 Rosen Dec 1982 A
4429080 Casey et al. Jan 1984 A
4440789 Mattei et al. Apr 1984 A
4441216 Ionescu et al. Apr 1984 A
4470157 Love Sep 1984 A
4494531 Gianturco Jan 1985 A
4506394 Bedard Mar 1985 A
4535483 Klawitter et al. Aug 1985 A
4549921 Wolfe, Jr. Oct 1985 A
4559945 Koelmel et al. Dec 1985 A
4564014 Fogarty Jan 1986 A
4580568 Gianturco Apr 1986 A
4591630 Gertzman et al. May 1986 A
4605730 Shalaby et al. Aug 1986 A
4624256 Messier et al. Nov 1986 A
4643732 Pietsch et al. Feb 1987 A
4643734 Lin Feb 1987 A
4653497 Bezwada et al. Mar 1987 A
4657024 Coneys Apr 1987 A
4661300 Daugherty Apr 1987 A
4665906 Jervis May 1987 A
4665918 Garza et al. May 1987 A
4666442 Arru et al. May 1987 A
4675361 Ward et al. Jun 1987 A
4692164 Dzemeshkevich Sep 1987 A
4700704 Jamiolkowski et al. Oct 1987 A
4731074 Rousseau et al. Mar 1988 A
4731075 Gallo Mezo et al. Mar 1988 A
4755593 Lauren Jul 1988 A
4759758 Gabbay Jul 1988 A
4762129 Bonzel Aug 1988 A
4776337 Palmaz Oct 1988 A
4787901 Baykut Nov 1988 A
4788979 Jarrett et al. Dec 1988 A
4791929 Jarrett et al. Dec 1988 A
4798611 Freeman Jan 1989 A
4800603 Jaffe Jan 1989 A
4806595 Noishiki et al. Feb 1989 A
4816028 Kapadia Mar 1989 A
4816029 Penny et al. Mar 1989 A
4832055 Palestrant May 1989 A
4836204 Landymore et al. Jun 1989 A
4838267 Jamiolkowski et al. Jun 1989 A
4851000 Gupta Jul 1989 A
4856510 Kowalewski Aug 1989 A
4856516 Hillstead Aug 1989 A
4861830 Ward et al. Aug 1989 A
4872875 Hwang Oct 1989 A
4893623 Rosenbluth Jan 1990 A
4902508 Badylak et al. Feb 1990 A
4911163 Fina Mar 1990 A
4917089 Sideris Apr 1990 A
4923465 Knock et al. May 1990 A
4952215 Ouriel et al. Aug 1990 A
4956178 Badylak et al. Sep 1990 A
4969458 Wiktor Nov 1990 A
4992027 Acosta Feb 1991 A
4994071 MacGregor Feb 1991 A
4994074 Bezwada et al. Feb 1991 A
4994077 Dobben Feb 1991 A
5007923 Bezwada et al. Apr 1991 A
5017664 Grasel et al. May 1991 A
5019085 Hillstead May 1991 A
5020612 Williams Jun 1991 A
5024671 Tu et al. Jun 1991 A
5024841 Chu et al. Jun 1991 A
5035706 Gianturco et al. Jul 1991 A
5037434 Lane Aug 1991 A
5041126 Gianturco Aug 1991 A
5047048 Bezwada et al. Sep 1991 A
5053008 Bajaj Oct 1991 A
5067491 Taylor, II et al. Nov 1991 A
5076807 Bezwada et al. Dec 1991 A
5080665 Jarrett et al. Jan 1992 A
5080670 Imamura et al. Jan 1992 A
5085629 Goldberg et al. Feb 1992 A
5100433 Bezwada et al. Mar 1992 A
5103817 Reisdorf et al. Apr 1992 A
5104402 Melbin Apr 1992 A
5104404 Wolff Apr 1992 A
5108420 Marks Apr 1992 A
5108425 Hwang Apr 1992 A
5110064 Kimura et al. May 1992 A
5116365 Hillstead May 1992 A
5116564 Jansen et al. May 1992 A
5133725 Quadri Jul 1992 A
5133755 Brekke Jul 1992 A
5139515 Robicsek Aug 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5171259 Inoue Dec 1992 A
5174295 Christian et al. Dec 1992 A
5176692 Wilk et al. Jan 1993 A
5178618 Kandarpa Jan 1993 A
5178632 Hanson Jan 1993 A
5178633 Peters Jan 1993 A
5192301 Kamiya et al. Mar 1993 A
5192313 Budd et al. Mar 1993 A
5197979 Quintero et al. Mar 1993 A
5197980 Gorshkov Mar 1993 A
5201314 Bosley et al. Apr 1993 A
5201757 Heyn et al. Apr 1993 A
5226889 Sheiban Jul 1993 A
5234457 Andersen Aug 1993 A
5239982 Trauthen Aug 1993 A
5258000 Gianturco Nov 1993 A
5275826 Badylak et al. Jan 1994 A
5281422 Badylak et al. Jan 1994 A
5282824 Gianturco Feb 1994 A
5284488 Sideris Feb 1994 A
5289831 Bosley Mar 1994 A
5293879 Vonk et al. Mar 1994 A
5306294 Winston et al. Apr 1994 A
5314444 Gianturco May 1994 A
5314472 Fontaine May 1994 A
5314473 Godin May 1994 A
5322062 Servas Jun 1994 A
5327891 Rammler Jul 1994 A
5334210 Gianturco Aug 1994 A
5334217 Das Aug 1994 A
5342387 Summers Aug 1994 A
5344426 Lau et al. Sep 1994 A
5352240 Ross Oct 1994 A
5358518 Camilli Oct 1994 A
5366473 Winston et al. Nov 1994 A
5366479 McGarry et al. Nov 1994 A
5370685 Stevens Dec 1994 A
5376113 Jansen et al. Dec 1994 A
5380320 Morris Jan 1995 A
5383892 Cardon et al. Jan 1995 A
5387235 Chuter Feb 1995 A
5389106 Tower Feb 1995 A
5393594 Koyfman et al. Feb 1995 A
5397311 Walker Mar 1995 A
5397331 Himpens et al. Mar 1995 A
5397355 Marin et al. Mar 1995 A
5405377 Cragg Apr 1995 A
5405381 Olin Apr 1995 A
5411552 Andersen May 1995 A
5412068 Tang et al. May 1995 A
5413599 Imachi et al. May 1995 A
5417708 Hall et al. May 1995 A
5421955 Lau et al. Jun 1995 A
5425744 Fagan et al. Jun 1995 A
5433727 Sideris Jul 1995 A
5441515 Khosravi et al. Aug 1995 A
5443496 Schwartz Aug 1995 A
5449373 Pinchasik Sep 1995 A
5451235 Lock et al. Sep 1995 A
5456713 Chuter Oct 1995 A
5468253 Bezwada et al. Nov 1995 A
5486193 Bourne Jan 1996 A
5486195 Myers et al. Jan 1996 A
5489297 Duran Feb 1996 A
5500014 Quijano Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5514154 Lau et al. May 1996 A
5522841 Roby et al. Jun 1996 A
5527354 Fontaine et al. Jun 1996 A
5530683 Lindberg Jun 1996 A
5540712 Kleshinski et al. Jul 1996 A
5540713 Schnepp-Pesch et al. Jul 1996 A
5545215 Duran Aug 1996 A
5549662 Fordenbacher Aug 1996 A
5549663 Cottone, Jr. Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554119 Harrison et al. Sep 1996 A
5554181 Das Sep 1996 A
5554185 Block et al. Sep 1996 A
5554389 Badylak et al. Sep 1996 A
5562728 Lazarus et al. Oct 1996 A
5562729 Purdy Oct 1996 A
5571168 Toro Nov 1996 A
5589563 Ward et al. Dec 1996 A
5591197 Orth et al. Jan 1997 A
5591198 Boyle et al. Jan 1997 A
5595571 Jaffe Jan 1997 A
5603698 Roberts et al. Feb 1997 A
5607442 Fischell et al. Mar 1997 A
5607445 Summers Mar 1997 A
5607465 Camilli Mar 1997 A
5609598 Laufer et al. Mar 1997 A
5613981 Boyle et al. Mar 1997 A
5624449 Pham et al. Apr 1997 A
5628791 Bokros et al. May 1997 A
5630829 Lauterjung May 1997 A
5632771 Boatman et al. May 1997 A
5634936 Linden et al. Jun 1997 A
5636641 Fariabi Jun 1997 A
5641324 Bokros et al. Jun 1997 A
5643312 Fischell et al. Jul 1997 A
5643317 Pavcnik et al. Jul 1997 A
5653727 Wiktor Aug 1997 A
5662675 Polansky et al. Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5668288 Storey et al. Sep 1997 A
5669933 Simon et al. Sep 1997 A
5681346 Orth et al. Oct 1997 A
5683411 Kavteladze et al. Nov 1997 A
5690642 Osborne et al. Nov 1997 A
5697971 Fischell et al. Dec 1997 A
5702372 Nelson Dec 1997 A
5702421 Schneidt Dec 1997 A
5705181 Cooper et al. Jan 1998 A
5707389 Louw et al. Jan 1998 A
5709707 Lock et al. Jan 1998 A
5711969 Patel et al. Jan 1998 A
5713920 Bezwada et al. Feb 1998 A
5713950 Cox Feb 1998 A
5713953 Vallana et al. Feb 1998 A
5720777 Jaffe Feb 1998 A
5725519 Penner Mar 1998 A
5725534 Rasmussen Mar 1998 A
5725572 Lam et al. Mar 1998 A
5728158 Lau et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5733337 Carr, Jr. et al. Mar 1998 A
5735893 Lau et al. Apr 1998 A
5741327 Frantzen Apr 1998 A
5749919 Blanc May 1998 A
5755776 Al-Saadon May 1998 A
5755777 Chuter May 1998 A
5755778 Kleshinski May 1998 A
5755781 Jayaraman May 1998 A
5759192 Saunders Jun 1998 A
5762625 Igaki Jun 1998 A
5766238 Lau et al. Jun 1998 A
5769780 Hata et al. Jun 1998 A
5769796 Palermo et al. Jun 1998 A
5772632 Forman Jun 1998 A
5776161 Globerman Jul 1998 A
5776188 Shepherd et al. Jul 1998 A
5779670 Melman et al. Jul 1998 A
5779729 Severini Jul 1998 A
5792114 Fiore Aug 1998 A
5792144 Fischell et al. Aug 1998 A
5797952 Klein Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5797953 Tekulve Sep 1998 A
5800456 Maeda et al. Sep 1998 A
5800526 Andersen et al. Sep 1998 A
5807404 Richter Sep 1998 A
5810847 Laufer et al. Sep 1998 A
5814061 Osborne et al. Sep 1998 A
5824041 Freislinger et al. Oct 1998 A
5824042 Lombardi et al. Oct 1998 A
5824045 Alt Oct 1998 A
5824049 Ragheb et al. Oct 1998 A
5824062 Patke et al. Oct 1998 A
5824063 Cox Oct 1998 A
5827237 Macoviak et al. Oct 1998 A
5833694 Poncet Oct 1998 A
5830209 Savage et al. Nov 1998 A
5833671 Macoviak et al. Nov 1998 A
5836964 Richter et al. Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5843090 Schuetz Dec 1998 A
5843117 Alt et al. Dec 1998 A
5843180 Jaffe et al. Dec 1998 A
5843181 Jaffe et al. Dec 1998 A
5846247 Unworth et al. Dec 1998 A
5846261 Kotula et al. Dec 1998 A
5851232 Lois Dec 1998 A
5853422 Huebsch et al. Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855600 Alt Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5861003 Latson et al. Jan 1999 A
5865723 Love Feb 1999 A
5876445 Andersen et al. Mar 1999 A
5876448 Thompson et al. Mar 1999 A
5879305 Yock et al. Mar 1999 A
5879366 Shaw et al. Mar 1999 A
5879382 Boneau Mar 1999 A
5885619 Patel et al. Mar 1999 A
5891128 Gia et al. Apr 1999 A
5891193 Robinson et al. Apr 1999 A
5891195 Klostermeyer et al. Apr 1999 A
5895419 Tweden et al. Apr 1999 A
5895420 Mirsch, II et al. Apr 1999 A
5902334 Dwyer et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5908452 Bokros et al. Jun 1999 A
5911732 Hojeibane Jun 1999 A
5925063 Khosravi Jul 1999 A
5926016 Pattantyus Jul 1999 A
5928248 Acker Jul 1999 A
5928258 Kahn Jul 1999 A
5935148 Villar et al. Aug 1999 A
5935161 Robinson Aug 1999 A
5937861 Augustine Aug 1999 A
5938682 Hojeibane Aug 1999 A
5944733 Engelson Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5947995 Samuels Sep 1999 A
5947997 Pavcnik et al. Sep 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5955110 Patel et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5960642 Kim et al. Oct 1999 A
5961546 Robinson et al. Oct 1999 A
5968096 Whitson et al. Oct 1999 A
5980565 Jayaraman Nov 1999 A
5980799 Martakos et al. Nov 1999 A
5981195 Fuller et al. Nov 1999 A
5993844 Abraham et al. Nov 1999 A
5997573 Quijano et al. Dec 1999 A
6004347 McNamara et al. Dec 1999 A
6007521 Melman Dec 1999 A
6010531 Donlon et al. Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6017363 Hojeibane Jan 2000 A
6022359 Frantzen et al. Feb 2000 A
6022374 Imran Feb 2000 A
6024690 Lee et al. Feb 2000 A
6027525 Suh et al. Feb 2000 A
6033398 Farley et al. Mar 2000 A
6036687 Laufer et al. Mar 2000 A
6042606 Frantzen Mar 2000 A
6053940 Wijay Apr 2000 A
6056775 Borghi et al. May 2000 A
6059757 Macoviak et al. May 2000 A
6059779 Mills May 2000 A
6059826 Bokros May 2000 A
6059827 Fenton May 2000 A
6063113 Kavteladze et al. May 2000 A
6074419 Healy et al. Jun 2000 A
6077281 Das Jun 2000 A
6077291 Das Jun 2000 A
6077295 Limon et al. Jun 2000 A
6077296 Shokoohi et al. Jun 2000 A
6080182 Shaw et al. Jun 2000 A
6090035 Campbell Jul 2000 A
6090127 Globerman Jul 2000 A
6096027 Layne Aug 2000 A
6096052 Callister et al. Aug 2000 A
6096070 Ragheb et al. Aug 2000 A
6099561 Alt Aug 2000 A
6099567 Badylak et al. Aug 2000 A
6100962 Kinoshita et al. Aug 2000 A
6110191 Dehdashtian Aug 2000 A
6110201 Quijano et al. Aug 2000 A
6110212 Gregory Aug 2000 A
6113623 Sgro Sep 2000 A
6117157 Tekulve Sep 2000 A
6117159 Huebsch et al. Sep 2000 A
6117979 Hendriks et al. Sep 2000 A
6123721 Jang Sep 2000 A
6126685 Lenker Oct 2000 A
6126686 Badylak et al. Oct 2000 A
6129755 Mathis et al. Oct 2000 A
6132460 Thompson Oct 2000 A
6132461 Thompson Oct 2000 A
6136025 Barbut et al. Oct 2000 A
6139575 Shu et al. Oct 2000 A
6143016 Bleam Nov 2000 A
6143022 Shull et al. Nov 2000 A
6146416 Andersen et al. Nov 2000 A
6149660 Laufer et al. Nov 2000 A
6149680 Shelso Nov 2000 A
6159237 Alt et al. Dec 2000 A
6162245 Jayaraman Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6168617 Blaeser et al. Jan 2001 B1
6174331 Moe et al. Jan 2001 B1
6176875 Lenker Jan 2001 B1
6178968 Louw et al. Jan 2001 B1
6179858 Squire et al. Jan 2001 B1
6183511 Patke et al. Feb 2001 B1
6183512 Howanec et al. Feb 2001 B1
6187036 Shaolian et al. Feb 2001 B1
6187039 Hiles et al. Feb 2001 B1
6190406 Durerig et al. Feb 2001 B1
6193731 Oppelt Feb 2001 B1
6197049 Shaolian et al. Mar 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6206907 Marino et al. Mar 2001 B1
6206931 Cook et al. Mar 2001 B1
6214029 Thill et al. Apr 2001 B1
6216493 Weston et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6231507 Zikorus et al. May 2001 B1
6231561 Frazier et al. May 2001 B1
6231598 Berry May 2001 B1
6235050 Quiachon et al. May 2001 B1
6235053 Jang May 2001 B1
6238409 Hojeibane May 2001 B1
6238416 Sideris May 2001 B1
6241763 Drasler et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6254611 Vrba Jul 2001 B1
6254631 Thompson Jul 2001 B1
6254636 Peredo Jul 2001 B1
6254642 Taylor Jul 2001 B1
6264700 Kilcoyne et al. Jul 2001 B1
6280467 Leonhardt Aug 2001 B1
6233968 Taheri Sep 2001 B1
6283990 Kanesaka Sep 2001 B1
6287330 Johansson et al. Sep 2001 B1
6287332 Bolz et al. Sep 2001 B1
6287334 Moll et al. Sep 2001 B1
6287336 Globerman et al. Sep 2001 B1
6293966 Frantzen Sep 2001 B1
6296657 Brucker Oct 2001 B1
6299604 Ragheb et al. Oct 2001 B1
6299635 Frantzen Oct 2001 B1
6299636 Schmitt et al. Oct 2001 B1
6299637 Shaolian Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6312474 Francis et al. Nov 2001 B1
6312549 Huang et al. Nov 2001 B1
6315793 Bokros et al. Nov 2001 B1
6319281 Patel Nov 2001 B1
6325819 Pavcnik et al. Dec 2001 B1
6328727 Frazier et al. Dec 2001 B1
6328763 Love et al. Dec 2001 B1
6334052 Nordstrand Dec 2001 B1
6334871 Dor et al. Jan 2002 B1
6334872 Termin et al. Jan 2002 B1
6336938 Kavteladze et al. Jan 2002 B1
6338730 Bonutti et al. Jan 2002 B1
6338740 Carpentier Jan 2002 B1
6340366 Wijay Jan 2002 B2
6342067 Mathis et al. Jan 2002 B1
6342070 Nguyen-Thien-Nhon Jan 2002 B1
6346074 Roth Feb 2002 B1
6348065 Brown et al. Feb 2002 B1
6352554 De Paulis Mar 2002 B2
6355052 Neuss et al. Mar 2002 B1
6355056 Pinheiro Mar 2002 B1
6355070 Andersen et al. Mar 2002 B1
6358228 Tubman et al. Mar 2002 B1
6358277 Duran Mar 2002 B1
6358284 Fearnot et al. Mar 2002 B1
6368338 Konya et al. Apr 2002 B1
6371961 Osborne et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6375679 Martyn et al. Apr 2002 B1
6375989 Badylak et al. Apr 2002 B1
6379365 Diaz Apr 2002 B1
6379710 Badylak Apr 2002 B1
6383216 Kavteladze et al. May 2002 B1
6383832 Stone May 2002 B1
6395018 Castaneda May 2002 B1
6409752 Boatman et al. Jun 2002 B1
6415631 Weston et al. Jul 2002 B1
6416542 Marcade et al. Jul 2002 B1
6425914 Wallace et al. Jul 2002 B1
6425916 Garrison Jul 2002 B1
6428570 Globerman Aug 2002 B1
6440163 Swanson et al. Aug 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6444229 Voytik-Harbin et al. Sep 2002 B2
6451052 Burmeister et al. Sep 2002 B1
6458137 Klint Oct 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6464720 Boatman Oct 2002 B2
6471718 Staehle Oct 2002 B1
6478819 Moe Nov 2002 B2
6482228 Norred Nov 2002 B1
6485500 Kokish et al. Nov 2002 B1
6485510 Camrud et al. Nov 2002 B1
6488702 Besselink Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508824 Flaherty et al. Jan 2003 B1
6508833 Pavcnik Jan 2003 B2
6508966 Castro et al. Jan 2003 B1
6514063 Acciai et al. Feb 2003 B2
6524336 Papazoglou et al. Feb 2003 B1
6527800 McGuckin, Jr. et al. Mar 2003 B1
6530951 Bates et al. Mar 2003 B1
6533807 Wolinsky et al. Mar 2003 B2
6544291 Taylor Apr 2003 B2
6547815 Myers et al. Apr 2003 B2
6553801 Chen Apr 2003 B2
6558415 Thompson May 2003 B2
6558418 Carpentier et al. May 2003 B2
6558429 Taylor May 2003 B2
6562065 Shanley May 2003 B1
6565597 Fearnot et al. May 2003 B1
6565600 Hojeibane May 2003 B2
6572650 Abraham et al. Jun 2003 B1
6579221 Peterson Jun 2003 B1
6579307 Sarac Jun 2003 B2
6579311 Makower Jun 2003 B1
6579538 Spievack Jun 2003 B1
6580568 Ozaki Jun 2003 B2
6582462 Andersen et al. Jun 2003 B1
6585761 Taheri Jul 2003 B2
6589230 Gla et al. Jul 2003 B2
6594880 Elsberry Jul 2003 B2
6596021 Lootz Jul 2003 B1
6598307 Love et al. Jul 2003 B2
6599275 Fischer, Jr. Jul 2003 B1
6602241 Makower et al. Aug 2003 B2
6602286 Strecker Aug 2003 B1
6605049 Wagner et al. Aug 2003 B1
6613002 Clark et al. Sep 2003 B1
6613086 Moe et al. Sep 2003 B1
6616680 Thielen Sep 2003 B1
6623506 McGuckin, Jr. et al. Sep 2003 B2
6623508 Shaw et al. Sep 2003 B2
6632196 Houser Oct 2003 B1
6638300 Frantzen Oct 2003 B1
6640412 Iancea Nov 2003 B2
6656206 Corcoran et al. Dec 2003 B2
6656216 Hossainy et al. Dec 2003 B1
6663661 Boneau Dec 2003 B2
6666885 Moe Dec 2003 B2
6666886 Tranquillo et al. Dec 2003 B1
6669724 Park et al. Dec 2003 B2
6673100 Diaz et al. Jan 2004 B2
6676694 Weiss Jan 2004 B1
6676698 McGuckin, Jr. et al. Jan 2004 B2
6678962 Love et al. Jan 2004 B1
6685739 DiMatteo et al. Feb 2004 B2
6689123 Pinchasik Feb 2004 B2
6692458 Forman et al. Feb 2004 B2
6706026 Goldstein et al. Mar 2004 B1
6716241 Wilder et al. Apr 2004 B2
6720402 Langer et al. Apr 2004 B2
6726715 Sutherland Apr 2004 B2
6730064 Ragheb et al. May 2004 B2
6730117 Tseng et al. May 2004 B1
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6746489 Dua et al. Jun 2004 B2
6749622 McGuckin, Jr. et al. Jun 2004 B2
6752826 Holloway et al. Jun 2004 B2
6752828 Thornton Jun 2004 B2
6761735 Eberhardt et al. Jul 2004 B2
6767362 Schreck Jul 2004 B2
6783499 Schwartz Aug 2004 B2
6786922 Schaeffer Sep 2004 B2
6790214 Kraemer et al. Sep 2004 B2
6790218 Jayaraman Sep 2004 B2
6790237 Stinson Sep 2004 B2
6821292 Pazienza et al. Nov 2004 B2
6823576 Austin Nov 2004 B2
6830584 Seguin Dec 2004 B1
6843802 Villalobos et al. Jan 2005 B1
6859986 Jackson Mar 2005 B2
6878162 Bales et al. Apr 2005 B2
6896690 Lambrecht May 2005 B1
6908481 Cribier Jun 2005 B2
6911037 Gainor et al. Jun 2005 B2
6915560 Austin Jul 2005 B2
6918929 Udipi et al. Jul 2005 B2
6921378 O'Keefe et al. Jul 2005 B2
6932829 Majercak Aug 2005 B2
6939377 Jayaraman et al. Sep 2005 B2
6945978 Hyde Sep 2005 B1
6945989 Betelia et al. Sep 2005 B1
6949113 Van Tassel et al. Sep 2005 B2
6949116 Solymar et al. Sep 2005 B2
6953332 Kurk et al. Oct 2005 B1
6958076 Acosta Oct 2005 B2
6960220 Marino et al. Nov 2005 B2
6962603 Brown et al. Nov 2005 B1
6974474 Pavcnik et al. Dec 2005 B2
6976995 Mathis et al. Dec 2005 B2
6994092 Van der Burg et al. Feb 2006 B2
6994717 Konya et al. Feb 2006 B2
7011671 Welch Mar 2006 B2
7018403 Pienknagura Mar 2006 B1
7018404 Holmberg et al. Mar 2006 B2
7018406 Seguin Mar 2006 B2
7018407 Wright et al. Mar 2006 B1
7025777 Moore Apr 2006 B2
7025780 Gabbay Apr 2006 B2
7025923 Harhen et al. Apr 2006 B2
7029493 Majercak et al. Apr 2006 B2
7044966 Svanidze et al. May 2006 B2
7060088 Fischell et al. Jun 2006 B1
7070616 Majercak et al. Jul 2006 B2
7081131 Thornton Jul 2006 B2
7101381 Ford et al. Sep 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7101396 Svanidze et al. Sep 2006 B2
7118600 Dua et al. Oct 2006 B2
7125418 Duran et al. Oct 2006 B2
7128073 van der Burg et al. Oct 2006 B1
7128756 Lowe et al. Oct 2006 B2
7128757 Osborne et al. Oct 2006 B2
7128759 Osborne et al. Oct 2006 B2
7144410 Marino et al. Dec 2006 B2
7147661 Chobotov et al. Dec 2006 B2
7153324 Case et al. Dec 2006 B2
7160320 Duran Jan 2007 B2
7163556 Xie et al. Jan 2007 B2
7172625 Shu et al. Feb 2007 B2
7179270 Makower Feb 2007 B2
7182779 Acosta et al. Feb 2007 B2
7186789 Hossainy et al. Mar 2007 B2
7195641 Palmaz et al. Mar 2007 B2
7232462 Schaeffer Jun 2007 B2
7247167 Gabbay Jul 2007 B2
7258697 Cox et al. Aug 2007 B1
7261732 Justino Aug 2007 B2
7273492 Cheng et al. Sep 2007 B2
7288105 Oman et al. Oct 2007 B2
7303571 Makower et al. Dec 2007 B2
7323010 Verona et al. Jan 2008 B2
7338520 Bailey et al. Mar 2008 B2
7347869 Hojeibane et al. Mar 2008 B2
7351256 Hojeibane et al. Apr 2008 B2
7354455 Stinson Apr 2008 B2
7361189 Case et al. Apr 2008 B2
7364587 Dong et al. Apr 2008 B2
7377938 Sarac et al. May 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7399315 Iobbi Jul 2008 B2
7402171 Osborne Jul 2008 B2
7435257 Lashinski et al. Oct 2008 B2
7445630 Lashinski et al. Nov 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7491942 Black et al. Feb 2009 B2
7503928 Case et al. Mar 2009 B2
7520894 Pavcnik et al. Apr 2009 B2
7524331 Birdsall Apr 2009 B2
7524332 Osborne et al. Apr 2009 B2
7534259 Lashinski et al. May 2009 B2
7544205 Flagle et al. Jun 2009 B2
7544207 Osborne et al. Jun 2009 B2
7547322 Sarac et al. Jun 2009 B2
7556645 Lashinski et al. Jul 2009 B2
7563276 Osborne et al. Jul 2009 B2
7563277 Case et al. Jul 2009 B2
7566336 Corcoran et al. Jul 2009 B2
7569071 Haverkost et al. Aug 2009 B2
7582110 Case et al. Sep 2009 B2
7585321 Cribier Sep 2009 B2
7594927 Majercak et al. Sep 2009 B2
7604661 Pavcnik et al. Oct 2009 B2
7618447 Case et al. Nov 2009 B2
7625395 Case et al. Dec 2009 B2
7625399 Case et al. Dec 2009 B2
7628803 Pavcnik et al. Dec 2009 B2
7628804 Flagle et al. Dec 2009 B2
7637937 Case et al. Dec 2009 B2
7641686 Lashinski et al. Jan 2010 B2
7648527 Agnew Jan 2010 B2
7653455 Cinader, Jr. Jan 2010 B2
7655288 Bauman et al. Feb 2010 B2
7655584 Biran et al. Feb 2010 B2
7658759 Case et al. Feb 2010 B2
7658762 Lashinski et al. Feb 2010 B2
7659219 Biran et al. Feb 2010 B2
7670366 Case et al. Mar 2010 B2
7678144 Bailey et al. Mar 2010 B2
7686844 Case et al. Mar 2010 B2
7736385 Agnew Jun 2010 B2
7739971 Chambers et al. Jun 2010 B2
7745532 Ruberti et al. Jun 2010 B2
7806921 Hoffman Oct 2010 B2
7815923 Johnson et al. Oct 2010 B2
7819836 Levine et al. Oct 2010 B2
7846199 Paul, Jr. et al. Dec 2010 B2
7846203 Cribier Dec 2010 B2
7850510 Farnsworth et al. Dec 2010 B2
7854759 Shirley Dec 2010 B2
7861570 Thomas Jan 2011 B2
7871430 Pavcnik et al. Jan 2011 B2
7918882 Pavcnik et al. Apr 2011 B2
7935144 Lashinski et al. May 2011 B2
7942887 Kraemer et al. May 2011 B2
7955375 Agnew Jun 2011 B2
7955376 Osborne et al. Jun 2011 B2
7955377 Melsheimer Jun 2011 B2
7964206 Suokas et al. Jun 2011 B2
7979150 Lin et al. Jul 2011 B2
7993410 Shin et al. Aug 2011 B2
8012201 Lashinski et al. Sep 2011 B2
8038708 Case et al. Oct 2011 B2
8038710 Fearnot et al. Oct 2011 B2
8048500 Drumheller et al. Nov 2011 B2
8048503 Farnsworth et al. Nov 2011 B2
8057532 Hoffman Nov 2011 B2
8057540 Letac et al. Nov 2011 B2
8092522 Paul, Jr. et al. Jan 2012 B2
8109990 Paul et al. Feb 2012 B2
8118877 Brauker et al. Feb 2012 B2
8128686 Paul, Jr. et al. Mar 2012 B2
8129477 Zhang et al. Mar 2012 B1
8133213 Lashinski et al. Mar 2012 B2
8133500 Ringeisen et al. Mar 2012 B2
8157810 Case et al. Apr 2012 B2
8157857 Case et al. Apr 2012 B2
8197534 Osborne et al. Jun 2012 B2
8211165 McIntosh et al. Jul 2012 B1
8221492 Case et al. Jul 2012 B2
8252043 Case et al. Aug 2012 B2
8257429 Pavcnik Sep 2012 B2
8273117 Palumbo et al. Sep 2012 B2
8276533 Chambers et al. Oct 2012 B2
8292938 Case Oct 2012 B2
8303648 Grewe et al. Nov 2012 B2
8303649 Agnew et al. Nov 2012 B2
8308796 Lashinski et al. Nov 2012 B2
8313526 Hoffman et al. Nov 2012 B2
8317853 Agnew Nov 2012 B2
8323332 Agnew Dec 2012 B2
8337545 Osborne Dec 2012 B2
8351126 Peng Jan 2013 B2
8366741 Chin et al. Feb 2013 B2
8366743 Zeng Feb 2013 B2
8377118 Lashinski et al. Feb 2013 B2
8403977 Case et al. Mar 2013 B2
8403979 Paul, Jr. Mar 2013 B2
8470020 Schaeffer et al. Jun 2013 B2
8475512 Hunt Jul 2013 B2
8475516 Paul et al. Jul 2013 B2
8506621 Agnew et al. Aug 2013 B2
8556881 Lashinski et al. Oct 2013 B2
8568477 Lashinski et al. Oct 2013 B2
8617205 Pavcnik et al. Dec 2013 B2
8652197 Paul et al. Feb 2014 B2
8663320 Chambers et al. Mar 2014 B2
8679175 Paul, Jr. et al. Mar 2014 B2
8702746 Tekulve et al. Apr 2014 B2
8771338 Schaeffer et al. Jul 2014 B2
10722365 Chambers Jul 2020 B2
20010001128 Holman et al. May 2001 A1
20010004707 Dereume et al. Jun 2001 A1
20010004715 Duran Jun 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010011187 Pavcnik et al. Aug 2001 A1
20010016770 Allen et al. Aug 2001 A1
20010018610 Limon Aug 2001 A1
20010020189 Taylor Sep 2001 A1
20010020190 Taylor Sep 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025197 Shu et al. Sep 2001 A1
20010034537 Shaw et al. Oct 2001 A1
20010037129 Thill Nov 2001 A1
20010039450 Pavcnik Nov 2001 A1
20010041930 Globerman et al. Nov 2001 A1
20010044648 Wolinsky et al. Nov 2001 A1
20010049553 De Paulis et al. Dec 2001 A1
20020002400 Drasler et al. Jan 2002 A1
20020019665 Dehdashtian et al. Feb 2002 A1
20020029994 Schon Mar 2002 A1
20020032414 Ragheb et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020038128 Turovkiy et al. Mar 2002 A1
20020052642 Cox et al. May 2002 A1
20020052651 Myers et al. May 2002 A1
20020055772 McGuckin, Jr. et al. May 2002 A1
20020065552 Jayaraman et al. May 2002 A1
20020065554 Streeter May 2002 A1
20020068866 Zikorus Jun 2002 A1
20020072794 Gabbay Jun 2002 A1
20020099439 Schwartz et al. Jul 2002 A1
20020111339 Klausener et al. Aug 2002 A1
20020111647 Khairkhahan et al. Aug 2002 A1
20020115559 Batchelor et al. Aug 2002 A1
20020120338 Boyer et al. Aug 2002 A1
20020123786 Gittings Sep 2002 A1
20020123790 White et al. Sep 2002 A1
20020123800 Taheri Sep 2002 A1
20020123802 Snyders Sep 2002 A1
20020129820 Ryan et al. Sep 2002 A1
20020138131 Solovay et al. Sep 2002 A1
20020138135 Duerig et al. Sep 2002 A1
20020169475 Gainor et al. Nov 2002 A1
20020173843 Peredo et al. Nov 2002 A1
20020177890 Lenker Nov 2002 A1
20020177894 Acosta et al. Nov 2002 A1
20020177899 Eum Nov 2002 A1
20020179098 Makower Dec 2002 A1
20020183787 Wahr et al. Dec 2002 A1
20020187288 Lim et al. Dec 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20020198563 Gainor et al. Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030014126 Patel et al. Jan 2003 A1
20030018968 Avnet Jan 2003 A1
20030023302 Moe et al. Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030028213 Thill et al. Feb 2003 A1
20030028233 Vardi et al. Feb 2003 A1
20030033009 Gabbay Feb 2003 A1
20030036794 Ragheb et al. Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030040808 Stack et al. Feb 2003 A1
20030055483 Gumm Mar 2003 A1
20030055492 Shaolian Mar 2003 A1
20030055496 Cai et al. Mar 2003 A1
20030069646 Stinson Apr 2003 A1
20030083730 Stinson May 2003 A1
20030083741 Woo et al. May 2003 A1
20030093071 Hauck et al. May 2003 A1
20030093108 Avellanet et al. May 2003 A1
20030093144 Jang May 2003 A1
20030097172 Shalev et al. May 2003 A1
20030109922 Peterson et al. Jun 2003 A1
20030114913 Spenser Jun 2003 A1
20030114919 McQuiston et al. Jun 2003 A1
20030120263 Ouriel et al. Jun 2003 A1
20030125790 Fastovsky et al. Jul 2003 A1
20030125791 Sequin et al. Jul 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130713 Stewart et al. Jul 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030135266 Chew et al. Jul 2003 A1
20030139805 Holmberg et al. Jul 2003 A1
20030139819 Beer et al. Jul 2003 A1
20030144670 Pavcnik et al. Jul 2003 A1
20030144694 Chanduszko et al. Jul 2003 A1
20030149471 Briana et al. Aug 2003 A1
20030153972 Helmus Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030163190 LaFont et al. Aug 2003 A1
20030171824 Abraham et al. Sep 2003 A1
20030176911 Iancea et al. Sep 2003 A1
20030176912 Chuter et al. Sep 2003 A1
20030176914 Rabkin et al. Sep 2003 A1
20030181968 Xie et al. Sep 2003 A1
20030181973 Sahota Sep 2003 A1
20030181974 Xie et al. Sep 2003 A1
20030187500 Jansen et al. Oct 2003 A1
20030191495 Ryan et al. Oct 2003 A1
20030191525 Thornton Oct 2003 A1
20030195618 Abraham et al. Oct 2003 A1
20030199747 Michlitsch Oct 2003 A1
20030199767 Cespedes Oct 2003 A1
20030199768 Cespedes Oct 2003 A1
20030206860 Bleyer et al. Nov 2003 A1
20030208224 Broome Nov 2003 A1
20030208254 Shortt Nov 2003 A1
20030208261 Thorpe Nov 2003 A1
20030209835 Chun Nov 2003 A1
20030212431 Brady et al. Nov 2003 A1
20030220683 Minasian et al. Nov 2003 A1
20030225445 Derus Dec 2003 A1
20030225446 Hartley Dec 2003 A1
20030225449 Denison Dec 2003 A1
20030236443 Cespedes Dec 2003 A1
20030236568 Hojeibane et al. Dec 2003 A1
20040006380 Buck et al. Jan 2004 A1
20040015230 Moll Jan 2004 A1
20040015232 Salazar Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040024444 Moore Feb 2004 A1
20040024447 Haverich Feb 2004 A1
20040024452 Kruse et al. Feb 2004 A1
20040029993 Klee et al. Feb 2004 A1
20040034409 Heublein et al. Feb 2004 A1
20040044401 Bales et al. Mar 2004 A1
20040044407 Verona Mar 2004 A1
20040047909 Ragheb Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059411 Strecker Mar 2004 A1
20040064067 Ward Apr 2004 A1
20040073155 Laufer et al. Apr 2004 A1
20040073230 Mulholland et al. Apr 2004 A1
20040073238 Makower Apr 2004 A1
20040073242 Chanduszko Apr 2004 A1
20040073297 Rohde et al. Apr 2004 A1
20040078053 Berg et al. Apr 2004 A1
20040093017 Chanduszko May 2004 A1
20040093061 Acosta et al. May 2004 A1
20040093070 Hojeibane et al. May 2004 A1
20040093073 Lowe et al. May 2004 A1
20040098030 Makower et al. May 2004 A1
20040098079 Hartley May 2004 A1
20040098098 McGucking et al. May 2004 A1
20040102806 Broome et al. May 2004 A1
20040102834 Nakano et al. May 2004 A1
20040102855 Shank May 2004 A1
20040106985 Jang Jun 2004 A1
20040111145 Serino et al. Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040117010 Houston et al. Jun 2004 A1
20040117031 Stack et al. Jun 2004 A1
20040122448 Levine Jun 2004 A1
20040127981 Rahdert et al. Jul 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040137042 Hiles et al. Jul 2004 A1
20040138737 Davidson et al. Jul 2004 A1
20040143277 Marino et al. Jul 2004 A1
20040143291 Corcoran et al. Jul 2004 A1
20040143292 Marino et al. Jul 2004 A1
20040143293 Marino et al. Jul 2004 A1
20040143294 Corcoran et al. Jul 2004 A1
20040148000 Bilge Jul 2004 A1
20040158331 Stack et al. Aug 2004 A1
20040166169 Malaviya et al. Aug 2004 A1
20040167566 Beulke et al. Aug 2004 A1
20040167619 Case et al. Aug 2004 A1
20040080352 Bleyer Sep 2004 A1
20040172141 Stack et al. Sep 2004 A1
20040176799 Chanduszko et al. Sep 2004 A1
20040180042 Cook et al. Sep 2004 A1
20040186558 Pavcnik Sep 2004 A1
20040210301 Obermiller Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040213756 Michal et al. Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040220610 Kreidler et al. Nov 2004 A1
20040224868 Meyerhoff et al. Nov 2004 A1
20040225344 Hoffa et al. Nov 2004 A1
20040225348 Case et al. Nov 2004 A1
20040225352 Osborne et al. Nov 2004 A1
20040225356 Frater Nov 2004 A1
20040230222 Van der Burg et al. Nov 2004 A1
20040230287 Hartley Nov 2004 A1
20040243216 Gregorich Dec 2004 A1
20040243218 Schaeffer Dec 2004 A1
20040243219 Fischer et al. Dec 2004 A1
20040243222 Osborne et al. Dec 2004 A1
20040249439 Richter et al. Dec 2004 A1
20040254640 Sutherland et al. Dec 2004 A1
20040260229 Meir Dec 2004 A1
20040260328 Zvuloni et al. Dec 2004 A1
20040260340 Jacobs et al. Dec 2004 A1
20040260389 Case Dec 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20040267191 Gifford, III et al. Dec 2004 A1
20040267306 Blaeser et al. Dec 2004 A1
20050004659 Von Oepen et al. Jan 2005 A1
20050010248 Lafontaine Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak et al. Jan 2005 A1
20050033398 Seguin Feb 2005 A1
20050034735 Deem et al. Feb 2005 A1
20050038501 Moore, Jr. et al. Feb 2005 A1
20050043708 Gleeson et al. Feb 2005 A1
20050043759 Chanduszko Feb 2005 A1
20050049634 Chopra Mar 2005 A1
20050055079 Duran et al. Mar 2005 A1
20050059923 Gamboa Mar 2005 A1
20050060024 Lee et al. Mar 2005 A1
20050065547 Marino et al. Mar 2005 A1
20050065548 Marino et al. Mar 2005 A1
20050065614 Stinson Mar 2005 A1
20050070794 Deal et al. Mar 2005 A1
20050070821 Deal et al. Mar 2005 A1
20050075713 Biancucci et al. Apr 2005 A1
20050075725 Rowe Apr 2005 A1
20050075726 Svanidze et al. Apr 2005 A1
20050075728 Nguyen et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050092335 Bertrand May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Case May 2005 A1
20050113686 Peckham et al. May 2005 A1
20050113910 Paniagua May 2005 A1
20050125032 Whisenant et al. Jun 2005 A1
20050125050 Carter Jun 2005 A1
20050137676 Richardson et al. Jun 2005 A1
20050137681 Shoemaker et al. Jun 2005 A1
20050143801 Aboul-Hosn Jun 2005 A1
20050143806 Phillips Jun 2005 A1
20050143807 Pavcnik Jun 2005 A1
20050149459 Andreas et al. Jul 2005 A1
20050154405 Kraemer et al. Jul 2005 A1
20050163818 Sung et al. Jul 2005 A1
20050171592 Majercak Aug 2005 A1
20050182483 Osborne et al. Aug 2005 A1
20050187565 Baker et al. Aug 2005 A1
20050187614 Agnew Aug 2005 A1
20050191496 Maschke Sep 2005 A1
20050192626 Widomski et al. Sep 2005 A1
20050192627 Whisenant et al. Sep 2005 A1
20050203568 Burg et al. Sep 2005 A1
20050216077 Mathis et al. Sep 2005 A1
20050222661 Case et al. Oct 2005 A1
20050228434 Amplatz et al. Oct 2005 A1
20050228479 Pavcnik et al. Oct 2005 A1
20050228486 Case Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050228505 Cornet et al. Oct 2005 A1
20050234509 Widomski et al. Oct 2005 A1
20050234541 Hunt et al. Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240255 Schaeffer Oct 2005 A1
20050249772 Malaviya et al. Nov 2005 A1
20050251201 Roue et al. Nov 2005 A1
20050256532 Nayak et al. Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267524 Chanduszko Dec 2005 A1
20050267526 Wahr et al. Dec 2005 A1
20050267560 Bates Dec 2005 A1
20050267573 Macoviak et al. Dec 2005 A9
20050273124 Chanduszko Dec 2005 A1
20050273153 Clerc et al. Dec 2005 A1
20050273160 Lashinski et al. Dec 2005 A1
20050283187 Longson Dec 2005 A1
20050288706 Widomski et al. Dec 2005 A1
20050288786 Chanduszko Dec 2005 A1
20060004433 Greenberg Jan 2006 A1
20060004436 Amarant et al. Jan 2006 A1
20060009800 Christianson et al. Jan 2006 A1
20060015178 Moaddeb et al. Jan 2006 A1
20060020332 Lashinski et al. Jan 2006 A1
20060020334 Lashinski et al. Jan 2006 A1
20060025844 Majercak et al. Feb 2006 A1
20060030923 Gunderson Feb 2006 A1
20060036282 Wahr et al. Feb 2006 A1
20060041302 Malewicz Feb 2006 A1
20060041319 Taylor et al. Feb 2006 A1
20060047338 Jenson et al. Mar 2006 A1
20060052816 Bates et al. Mar 2006 A1
20060052821 Abbott et al. Mar 2006 A1
20060058865 Case et al. Mar 2006 A1
20060058889 Case et al. Mar 2006 A1
20060064152 Olson Mar 2006 A1
20060069430 Rahdert et al. Mar 2006 A9
20060074352 Case et al. Apr 2006 A1
20060074480 Bales et al. Apr 2006 A1
20060089708 Osse et al. Apr 2006 A1
20060100531 Moser May 2006 A1
20060106418 Seibold et al. May 2006 A1
20060106420 Dolan et al. May 2006 A1
20060106454 Osborne May 2006 A1
20060106456 Machold et al. May 2006 A9
20060111770 Pavcnik et al. May 2006 A1
20060111773 Rittgers et al. May 2006 A1
20060116548 Case et al. Jun 2006 A1
20060116572 Case Jun 2006 A1
20060122646 Corcoran et al. Jun 2006 A1
20060136044 Osborne et al. Jun 2006 A1
20060136045 Flagle et al. Jun 2006 A1
20060155327 Briganti et al. Jul 2006 A1
20060167468 Gabbay Jul 2006 A1
20060173532 Flagle et al. Aug 2006 A1
20060178729 Thielen et al. Aug 2006 A1
20060178730 Hill et al. Aug 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060184239 Andrieu et al. Aug 2006 A1
20060195004 Jarvik Aug 2006 A1
20060200196 Zang et al. Sep 2006 A1
20060201996 Hodde Sep 2006 A1
20060210597 Hiles Sep 2006 A1
20060210603 Williams et al. Sep 2006 A1
20060212107 Case et al. Sep 2006 A1
20060212110 Osborne et al. Sep 2006 A1
20060212111 Case et al. Sep 2006 A1
20060216326 Pacetti Sep 2006 A1
20060217760 Widomski et al. Sep 2006 A1
20060217761 Opolski Sep 2006 A1
20060229670 Bates Oct 2006 A1
20060229702 Agnew Oct 2006 A1
20060230592 Heaney Oct 2006 A1
20060235467 DeVore Oct 2006 A1
20060235511 Osborne Oct 2006 A1
20060241675 Johnson et al. Oct 2006 A1
20060241744 Beith Oct 2006 A1
20060247762 Acosta et al. Nov 2006 A1
20060253188 Case Nov 2006 A1
20060259115 Case et al. Nov 2006 A1
20060259128 Pavcnik et al. Nov 2006 A1
20060259136 Nguyen Nov 2006 A1
20060265053 Hunt Nov 2006 A1
20060271030 Francis et al. Nov 2006 A1
20060271159 Gregorich et al. Nov 2006 A1
20060276813 Greenberg Dec 2006 A1
20060276882 Case Dec 2006 A1
20060282157 Hill et al. Dec 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20070016306 Dua et al. Jan 2007 A1
20070021826 Case Jan 2007 A1
20070027460 Case et al. Feb 2007 A1
20070027535 Purdy et al. Feb 2007 A1
20070027549 Godin Feb 2007 A1
20070038291 Case Feb 2007 A1
20070043431 Melsheimer Feb 2007 A1
20070056346 Spenser Mar 2007 A1
20070061002 Paul, Jr. et al. Mar 2007 A1
20070061009 Spenser Mar 2007 A1
20070088424 Greenberg Apr 2007 A1
20070093887 Case et al. Apr 2007 A1
20070100435 Case May 2007 A1
20070106372 Osborne et al. May 2007 A1
20070112423 Chu May 2007 A1
20070112437 Shank May 2007 A1
20070129738 Kraemer et al. Jun 2007 A1
20070135826 Zaver et al. Jun 2007 A1
20070162057 Kraemer et al. Jul 2007 A1
20070162058 Kraemer et al. Jul 2007 A1
20070162103 Case Jul 2007 A1
20070167961 Kraemer et al. Jul 2007 A1
20070173919 Maschke Jul 2007 A1
20070185560 Roeder et al. Aug 2007 A1
20070185565 Schwammenthal et al. Aug 2007 A1
20070208429 Leahy Sep 2007 A1
20070213813 Segesser et al. Sep 2007 A1
20070225798 Gregorich Sep 2007 A1
20070227518 Case Oct 2007 A1
20070233237 Krivoruchko Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070260263 Case et al. Nov 2007 A1
20070260327 Case et al. Nov 2007 A1
20070270931 Leanna Nov 2007 A1
20070270932 Headley Nov 2007 A1
20070270937 Leanna Nov 2007 A1
20070288086 Kalmann et al. Dec 2007 A1
20070288087 Gabbay Dec 2007 A1
20080009934 Schneider Jan 2008 A1
20080046071 Pavcnik Feb 2008 A1
20080051879 Case et al. Feb 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080091235 Sirota Apr 2008 A1
20080103582 Randall et al. May 2008 A1
20080125860 Webler et al. May 2008 A1
20080140110 Spence Jun 2008 A1
20080200936 Kraemer et al. Aug 2008 A1
20080200937 Kraemer et al. Aug 2008 A1
20080208215 Kraemer et al. Aug 2008 A1
20080221656 Hartley Sep 2008 A1
20080228206 Kraemer et al. Sep 2008 A1
20080228285 Kraemer et al. Sep 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20080249538 Kraemer et al. Oct 2008 A1
20080249609 Shanley Oct 2008 A1
20080249612 Osborne et al. Oct 2008 A1
20080249619 Stacchino et al. Oct 2008 A1
20080275470 Kraemer et al. Nov 2008 A1
20080281337 Kraemer et al. Nov 2008 A1
20080287966 Kraemer et al. Nov 2008 A1
20080312735 Thorpe et al. Dec 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090018649 Jaffe et al. Jan 2009 A1
20090062836 Kurrus Mar 2009 A1
20090062844 Tekulve Mar 2009 A1
20090082858 Nugent et al. Mar 2009 A1
20090088836 Bishop et al. Apr 2009 A1
20090099653 Suri et al. Apr 2009 A1
20090105813 Chambers Apr 2009 A1
20090118712 Carter et al. May 2009 A1
20090132037 Hoffman May 2009 A1
20090177275 Case Jul 2009 A1
20090216321 Osborne et al. Aug 2009 A1
20090234434 Johnson et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090248132 Bloom et al. Oct 2009 A1
20090264991 Paul et al. Oct 2009 A1
20090270965 Sinha et al. Oct 2009 A1
20090287300 Dave et al. Nov 2009 A1
20090292350 Eberhardt Nov 2009 A1
20100023114 Chambers et al. Jan 2010 A1
20100030246 Pavcnik et al. Feb 2010 A1
20100030259 Pavcnik et al. Feb 2010 A1
20100030314 Case et al. Feb 2010 A1
20100036484 Hariton Feb 2010 A1
20100057191 Pavcnik et al. Mar 2010 A1
20100063577 Case et al. Mar 2010 A1
20100114296 Case et al. May 2010 A1
20100114300 Case et al. May 2010 A1
20100121461 Sobrino-Serrano et al. May 2010 A1
20100121462 Sobrino-Serrano et al. May 2010 A1
20100131055 Case et al. May 2010 A1
20100137998 Sobrino-Serrano et al. Jun 2010 A1
20100174364 Hoffman Jul 2010 A1
20100185277 Braido Jul 2010 A1
20110054497 Kraemer et al. Mar 2011 A1
20110087198 Carter et al. Apr 2011 A1
20110087337 Forsell Apr 2011 A1
20110098800 Braido Apr 2011 A1
20110160753 Bastin Jun 2011 A1
20110190796 Kraemer et al. Aug 2011 A1
20110190905 Behan Aug 2011 A1
20110202078 Kraemer et al. Aug 2011 A1
20120053681 Alkhatib Mar 2012 A1
20120071969 Li Mar 2012 A1
20120078347 Braido Mar 2012 A1
20120089223 Nguyen Apr 2012 A1
20120130476 Paul et al. May 2012 A1
20120185038 Fish Jul 2012 A1
20120197390 Alkhatib Aug 2012 A1
20120203327 Case et al. Aug 2012 A1
20120253446 Osborne et al. Oct 2012 A1
20120253450 Case et al. Oct 2012 A1
20120323306 Case et al. Dec 2012 A1
20120330413 Pavcnik Dec 2012 A1
20130018453 Case et al. Jan 2013 A1
20130079867 Hoffman et al. Mar 2013 A1
20130079868 Agnew Mar 2013 A1
20130110254 Osborne May 2013 A1
20130116720 Theobald et al. May 2013 A1
20130123768 Harlan May 2013 A1
20130150956 Yohanan Jun 2013 A1
20130226291 Pavcnik et al. Aug 2013 A1
20130289706 Schaeffer et al. Oct 2013 A1
20140000112 Braido Jan 2014 A1
20140005776 Braido Jan 2014 A1
20140107691 Lashinski Apr 2014 A1
20140143236 Thompson et al. May 2014 A1
20140155987 Paul et al. Jun 2014 A1
20140155997 Braido Jun 2014 A1
20140163667 Lashinski et al. Jun 2014 A1
20140228937 Krieger et al. Aug 2014 A1
20150230923 Levi Aug 2015 A1
20160067031 Kassab Mar 2016 A1
20160175095 Dienno Jun 2016 A1
20170128212 Chambers May 2017 A1
Foreign Referenced Citations (175)
Number Date Country
2003265468 Aug 2002 AU
2002248669 Oct 2002 AU
2004220576 Sep 2004 AU
2381787 Mar 2001 CA
2401996 Mar 2001 CA
2403030 Sep 2002 CA
2518867 Sep 2004 CA
2523262 Nov 2004 CA
2246526 Mar 1973 DE
19851846 May 2000 DE
10223399 Dec 2003 DE
103546 Mar 1984 EP
0350302 Jan 1990 EP
0357003 Mar 1990 EP
0386936 Sep 1990 EP
0520126 Nov 1991 EP
0460428 Dec 1991 EP
0493788 Jul 1992 EP
0592410 Apr 1994 EP
0657147 Jun 1995 EP
0732089 Sep 1996 EP
0800801 Jun 1997 EP
0792627 Sep 1997 EP
0808614 Nov 1997 EP
0850607 Jul 1998 EP
0938880 Sep 1999 EP
1057460 Dec 2000 EP
1179321 Feb 2002 EP
1230901 Aug 2002 EP
1362563 Nov 2003 EP
1472996 Apr 2004 EP
1615595 Apr 2004 EP
1579886 Sep 2005 EP
1434538 Jan 2007 EP
1626681 Jul 2009 EP
1603492 Dec 2009 EP
1615593 Jan 2010 EP
2163224 Mar 2010 EP
2201911 Jun 2010 EP
1229865 Nov 2010 EP
2120795 Jul 2011 EP
2222247 Aug 2012 EP
1887980 Sep 2012 EP
1928512 Nov 2012 EP
1659992 Mar 2013 EP
2722678 Jul 1994 FR
2785174 May 2000 FR
2788217 Jul 2000 FR
2828091 Feb 2003 FR
1598111 Apr 1977 GB
2056023 Mar 1981 GB
0386936 Aug 2004 GB
S61137556 Jun 1986 JP
S62-227352 Oct 1987 JP
02-307480 Dec 1990 JP
4383707 Oct 2009 JP
4589395 Dec 2010 JP
4624984 Dec 2010 JP
4940388 Mar 2012 JP
1258406 Sep 1986 SU
1271508 Nov 1986 SU
1371701 Feb 1988 SU
WO8302225 Jul 1983 WO
WO8501651 Apr 1985 WO
WO9014804 Dec 1990 WO
WO9117720 Nov 1991 WO
WO9209247 Nov 1991 WO
WO9217118 Oct 1992 WO
WO9407560 Apr 1994 WO
WO9527448 Oct 1995 WO
WO9637167 Nov 1996 WO
WO9640008 Dec 1996 WO
WO9640011 Dec 1996 WO
WO9724082 Jul 1997 WO
WO9725937 Jul 1997 WO
WO9728744 Aug 1997 WO
WO9732543 Sep 1997 WO
WO9819732 Nov 1997 WO
WO9822045 May 1998 WO
WO9825636 Jun 1998 WO
WO9825637 Jun 1998 WO
WO9826291 Jun 1998 WO
WO9827868 Jul 1998 WO
WO9846165 Oct 1998 WO
WO9858600 Dec 1998 WO
WO9915224 Apr 1999 WO
WO9933414 Jul 1999 WO
WO9959503 Nov 1999 WO
WO9962431 Dec 1999 WO
WO0040176 Jul 2000 WO
WO0042950 Jul 2000 WO
WO0047134 Aug 2000 WO
0067679 Nov 2000 WO
WO0064380 Nov 2000 WO
WO0067661 Nov 2000 WO
WO0112105 Feb 2001 WO
0119285 Mar 2001 WO
WO0128459 Apr 2001 WO
WO0130275 May 2001 WO
WO0149213 Jul 2001 WO
WO0154625 Aug 2001 WO
WO0156500 Aug 2001 WO
WO0166035 Sep 2001 WO
WO0166037 Sep 2001 WO
WO0166043 Sep 2001 WO
WO0166190 Sep 2001 WO
WO0174273 Oct 2001 WO
WO200183017 Nov 2001 WO
WO0207601 Jan 2002 WO
WO2002024119 Mar 2002 WO
WO0236045 May 2002 WO
WO0239888 May 2002 WO
WO0241764 May 2002 WO
WO0243620 Jun 2002 WO
WO0249541 Jun 2002 WO
WO02102284 Dec 2002 WO
WO03002165 Jan 2003 WO
WO03011195 Feb 2003 WO
WO03030776 Apr 2003 WO
WO03030782 Apr 2003 WO
WO03047468 Jun 2003 WO
WO03063733 Aug 2003 WO
WO03088872 Oct 2003 WO
WO03101346 Dec 2003 WO
WO2003101346 Dec 2003 WO
WO2004016200 Feb 2004 WO
WO2004016201 Feb 2004 WO
WO2004045703 Jun 2004 WO
WO2004080352 Sep 2004 WO
WO2004082528 Sep 2004 WO
WO2004082530 Sep 2004 WO
WO2004089253 Oct 2004 WO
WO2004091449 Oct 2004 WO
2004096100 Nov 2004 WO
WO2004093745 Nov 2004 WO
WO2004103222 Dec 2004 WO
WO2004105651 Dec 2004 WO
WO2005011535 Feb 2005 WO
WO2005020612 Mar 2005 WO
WO05062931 Jul 2005 WO
WO2005082289 Sep 2005 WO
WO2005099623 Oct 2005 WO
WO2005099628 Oct 2005 WO
WO2006026325 Mar 2006 WO
WO2006028821 Mar 2006 WO
WO2006031436 Mar 2006 WO
2006050460 May 2006 WO
WO2006071245 Jul 2006 WO
WO2006124647 Nov 2006 WO
WO2006125055 Nov 2006 WO
WO2007047945 Apr 2007 WO
WO2007061801 May 2007 WO
WO2007092274 Aug 2007 WO
WO07108857 Sep 2007 WO
2007123658 Nov 2007 WO
WO2007130614 Nov 2007 WO
WO2007139677 Dec 2007 WO
WO2007142935 Dec 2007 WO
WO2008073582 Jun 2008 WO
WO2008094706 Aug 2008 WO
WO2008101083 Aug 2008 WO
WO08150529 Dec 2008 WO
WO2009052340 Apr 2009 WO
WO2009073774 Jun 2009 WO
WO2009088957 Jul 2009 WO
WO2009129481 Oct 2009 WO
WO2010042950 Apr 2010 WO
WO2010080884 Jul 2010 WO
WO2010091188 Aug 2010 WO
WO2010099209 Sep 2010 WO
WO2011109450 Sep 2011 WO
WO2012051489 Apr 2012 WO
WO2013120082 Aug 2013 WO
WO03092554 Nov 2013 WO
WO2014124356 Aug 2014 WO
Non-Patent Literature Citations (50)
Entry
Kinney, T.E., et al., “Acute, reversible tricuspid insufficiency: creation in canine model,” Am. J. Physiol. Heart Circ. Physiol. 260: H638-H641, 1991.
Bai, Yuan, et al., “Percutaneous establishment of tricuspid regugitation: an experimental model for transcatheter tricuspid valve replacement,” Chin. Med. J. 2010; 123(7), pp. 806-809.
Lamba, et al., “Degradation of Polyurethanes,” Polyurethanes in Biomedical Applications, 181-204, 1998.
Matthias Chiquet, “Regulation of extracellular matrix gene expression by mechanical stress,” Matrix Biol., 417-426, 1999.
Marcy Wong, Mark Siegrist, Xuesong Cao, “Cyclic compression of articular cartilage explants is associated with progressive consolidation and altered expression pattern of extracellular matrix proteins,” Matrix Biology, 391-399, 1999.
Alan J. Grodzinsky, Marc E. Levenston, Moonsoo Jin, Eliot H. Frank, “Cartilage Tissue Remodeling in Response to Mechanical Forces,” Annual Review of Biomedical Engineering, 691-713, 2000.
V.C. Mudera, R. Pleass, M. Eastwood, R. Tarnuzzer, G. Schultz, P. Khaw, D.A. Mcgrouther, R.A. Brown, “Molecular Responses of Human Dermal Fibroblasts to Dual Cues: Contact Guidance and Mechanical Load,” Cell Motility and the Cytoskeleton, 45: 1-9, 2000.
Christof Schild, Beat Trueb, “Mechanical Stress is Required for High-Level Expression of Connective Tissue Growth Factor,” Experimental Cell Research, 274: 83-91, 2002.
Heeschen, Christopher, et al., “Nicotine Stimulates Angiogensis and Promotes Tumor Growth and Atherosclerosis”, Nature Medicine vol. 7, No. 7, (Jul. 2001), pp. 833-839.
Johnson, Chad, et al., “Matrix Metalloproteinase-9 is Required for Adequate Angiogenic Revascularization of Ischemic Tissues”, Circulation Research, Feb. 6, 2004, No. 94, pp. 262-268.
Jux, Christian, et al., “A New Biological Matrix for Septal Occlusion”, Journal of Interventional Cardiology, vol. 16, No. 2, (2003), pp. 149-152.
King, Terry D., et al., “Secundum Atrial Septal Defect-Nonoperative Closure During Cardiac Catheterization”, JAMA, vol. 235, No. 23, Jun. 7, 1978, pp. 2506-2509.
Mullen, Michael J., et al., “BioSTAR Evaluation STudy (BEST) A Prospective, Multicenter, Phase I Clinic Trial to Evaluate the Feasibility, Efficacy, and Safety of the BioSTAR Bioabsorbable Septal Repair Implant for the Closure of Atrial-Level Shunts”, Circulation, Oct. 31, 2006, pp. 19621967.
Oguchi, M., et al., “Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis”, International Journal of Radiation Oncology Biology Physics, Mar. 15, 1998, vol. 40, No. 5, p. 1033-1037.
Pavcnik, Dusan et al., “Monodisk: Device for Percutaneous Transcatheter Closure of Cardiac Septal Defects”, Cardiovasc Intervent Radio (1993) vol. 16, pp. 308-312.
Rashkind, William J., “Transcatheter Treatment of Congenital Heart Disease”, Circulation vol. 67, No. 4, Apr. 1983, pp. 711-716.
Sideris, E.B. et al., “Transvenous Atrial Septal Defect Occlusion in Piglets with a ‘Buttoned’ Double-Disk Device”, Circulation, vol. 81, No. 1, Jan. 1990, pp. 312-318.
Jux, Christian, et al., “Interventional Atrial Septal Defect Closure Using a Totally Bioresorbable Occluder Matrix”, JACC, vol. 48, No. 1 (2006), pp. 161-169.
Babic, Uros U., et al., “Transcatheter Closure of Atrial Septal Defects”, The Lancet, Sep. 1, 1990, pp. 566-567.
Bhattathiri, VN, et al., “Influence of plasma GSH level on acute radiation mucositis of the oral cavity”, International Journal of Radiation Oncology Biology Physics (1994), vol. 29, No. 2, pp. 383-386.
Braun, M., et al., “Transcatheter Closure of Patent Foramen Ovale (PFO) in Patients With Paradoxical Embolism”, European Heart Journal (2004), vol. 25, pp. 424-430.
Das, Gladwin S., et al., “Experimental Atrial Septal Defect Closure With a New, Transcatheter, Self-Centering Device”, Circulation, vol. 88, No. 4, Part 1, Oct. 1993, pp. 1754-1764.
Lurie, Fedor Mechanism of Venous Valve Closure and Role of the Valve in Circulation: A New Concept, J Vasc Surg 2003;38:955-61. Elsevier, Amsterdam, The Netherlands.
Lurie, Fedor, The Mechanism of Venous Valve Closure in Normal Physiologic Conditions, J Vasc Surg 2002;35:713-17. Elsevier, Amsterdam, The Netherlands.
Van Bemmelen, Paul S. and Fedor Lurie, Letters to the Editor, Regarding “The Mechanism of Venous Valve Closure in Normal Physiological Conditions”, J Vasc Surg 2003; 37(1) 237-38. Elsevier, Amsterdam, The Netherlands.
Garcia-Rinaldi, Raul, Implantation of Cryopreserved Allograft Pulmonary Monocusp Patch, Tex Heart Inst J 2002;29:92-99. Texas Heart Institute, Houston, TX, USA.
Garcia-Rinaldi, Raul, Femoral Vein Valve Incompetence: Treatment with a Xenograft Monocusp Patch, J Vasc Surg 1986; 932-35. Elsevier, Amsterdam, The Netherlands.
Dana E. Perrin, James P. English, “Polycaprolactone,” Handbook of Bioabsorbable Polymers, 1997, 63-76.
Yuan et al. Geometrical Design and Finite Element Analysis on the Bioprosthetic Heart Valve. International Journal of Innovative Computing, Information and Control. vol. 3 No. 5. Oct. 2007. pp. 1289-1299. [abstract].
Yi-Shuan Li, John Y.-J Shyy, Song Li, Jongdae Lee, Bing US, Michael Karin, Shu Chien, “The Ras-JNK Pathway Is Involved in Shear-Induced Gene Expression,” Molecular and Cellular Biology, 1996, 5947-5954.
Wai Hung Wong, David J. Mooney, “Synthesis and Properties of Biodegradable Polymers Used as Synthetic Matrices for Tissue Engineering,” I synthetic Biodegradable Polymer Scaffolds, 1997, 51-82.
Schneider (Eur.) AG v. Scimed Life Sys., 852 F. Supp. 813 (D. Minn. 1994).
Bergan, John J., et al., “Chronic Venous Disease,” N. Engl. J. Med. 2006; 355: 488-98.
Dougal et al., “Stent Design: Implications for Restenosis,” Rev. Cardiovasc Med. 3 (suppl. 5), S16-S22 (2002).
Shu Chien, Song Li, John Y-J Shyy, “Effects of Mechanical Forces on Signal Transdution and Gene Expression in Endothelial Cells,” Hypertension 31, 162-169, 1998.
Stephen Badylak, Ph.D., M.D., Klod Lokini, Ph.D., Bob Tullius, M.S., Abby Simmons-Byrd, R.V.T., and Robert Morff, PH.D., “Morphologic Study of Small Intestinal Submucosa as a Body Wall Repair Device,” Journal of Surgical Research, 103, 190-202 (2002).
Elias Brountzos, Md, Dusan Pavcnik, Md, PhD, Hans A. Timmermans, BFA, Christopher Corless, Md, PhD, Barry T. Uchida, BS, Edith S, Nihsen, BA, Manabu Nakata, Md, PhD, Maria Schoder, Md, John A. Kaufman, Md, Frederick S. Keller, Md, and Josef Rosch, Md, “Remodeling of Suspended Small Intestinal Submucosa Venous Valve: An Experimental Study in Sheep to Assess the Host Cells' Origin,” J. Vasc. Interv. Radiol, 2003 14:349-356.
Stephen S. Kim, Satoshi Kaihara, Mark S. Benvenuto, Byung-Soo Kim, David J. Mooney, and Joseph P. Vacanti, “Small Intestinal Submucosa as a Small-Caliber Venous Graft: A Novel Model for Hepatocyte Transplantation on Synthetic Biodegradable Polymer Scaffolds with Direct Access to the Portal Venous System,” Journal of Pediatric Surgery, vol. 34, No. 1 (1999) 124-128.
G.E. Sandusky, Jr., S.F. Badylak, R.J. Morff, W.D. Johnson, and G. Lantz, “Histologic Findings After In Vivo Placement of Small Intestine Submucosal Vascular Grafts and Saphenous Vein Grafts in the Carotid Artery in Dogs,” American Journal of Pathology, vol. 140, No. 2 1992, 317-324.
D.K. Gilding, A.M. Reed, “Biodegradable polymers for use in surgery—polyglycolic/poly(actic acid) homo- and copolymers: 1,” Polymer, 1997, vol. 20, 1459-1464.
D.K. Gilding, “Biodegradable Polymers,” Biocompatibility of Clinical Implant Materials, Chap. 9, pp. 209-232, 1981.
Gabriel Helmlinger, Bradford C. Berk, Robert M. Nerem, “Calcium responses of endothelial cell monolayers subjected to pulsatile and steady laminar flow differ,” Am. J. Physiol. Cell Physiol., 269: C367-C375, 1995.
Matthias Chiquet, Mark Matthisson, Manuel Koch, Michael Tannheimer, Ruth Chiquet-Ehrismann, “Regulation of extracellular matrix synthesis by mechanical stress,” Biochem. Cell Biol. 74, 737-744 (1996).
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/377,619, dated Jul. 6, 2015, pp. 1-188.
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/377,619, dated Dec. 18, 2015, pp. 1-17.
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/377,619, dated Sep. 8, 2016, pp. 1-13.
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/377,619, dated Apr. 6, 2017, pp. 1-24.
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/377,619, dated Nov. 1, 2017, pp. 1-33.
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/377,619, dated Jul. 3, 2018, pp. 1-16.
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/377,619, dated Nov. 21, 2018, pp. 1-11.
Related Publications (1)
Number Date Country
20180055635 A1 Mar 2018 US
Provisional Applications (1)
Number Date Country
61763107 Feb 2013 US
Continuations (1)
Number Date Country
Parent 14176364 Feb 2014 US
Child 15804049 US